Cancer Research and Treatment

Hee Kyung Ahn

18 Articles

Head and Neck cancer

A Phase II Trial of Nintedanib in Patients with Metastatic or Recurrent Head and Neck Squamous Cell Carcinoma: In-Depth Analysis of Nintedanib Arm from the KCSG HN 15-16 TRIUMPH Trial: Kyoo Hyun Kim, Sun Min Lim, Hee Kyung Ahn, Yun-Gyoo Lee, Keun-Wook Lee, Myung-Ju Ahn, Bhumsuk Keam, Hye Ryun Kim, Hyun Woo Lee, Ho Jung An, Jin-Soo Kim; Cancer Res Treat. 2024;56(1):37-47. Published online July 20, 2023; DOI: https://doi.org/10.4143/crt.2023.433

Purpose
Precision oncology approach for recurrent and metastatic head and neck squamous cell carcinoma (HNSCC) is necessary due to its dismal prognosis. We performed a genomic profile-based umbrella trial of patients with platinum-refractory HNSCC (KCSG-TRIUMPH). Here, we present an in-depth report of the the nintedanib arm (arm 3) of the current trial.
Materials and Methods
The TRIUMPH study was a multicenter, open-label, single-arm phase 2 trial, in which patients were assigned to treatment arms based on next-generation sequencing (NGS)–based, matching genomic profiles. Patients whose tumors harbor fibroblast growth factor receptor (FGFR) alteration were enrolled in the nintedanib arm (arm 3) as part of the TRIUMPH study. The primary endpoint was the overall response rate (ORR), and secondary endpoints included overall survival (OS), progression-free survival (PFS), safety, and biomarker analysis.
Results
Between October 2017 and August 2020, 207 were enrolled in the TRIUMPH study, and eight were enrolled in the nintedanib arm. ORR and disease control rate were 42.9% and 57.1%, respectively. The median PFS was 5.6 months and the median duration of response was 9.1 months. Median OS was 11.1 months. One patient maintained the partial response for 36 months. Overall, the toxicity profiles were manageable.
Conclusion
Single-agent nintedanib has demonstrated significant efficacy in FGFR-mutated, recurrent or metastatic HNSCC patients, with tolerable toxicity profiles. The results from the study have provided the basis for routine NGS screening and FGFR-targeted therapy. Because of the small number of patients due to slow accrual in this study, further studies with a larger cohort are warranted for statistical power.

Citations

Citations to this article as recorded by

Targeting fibroblast growth factor receptor (FGFR) with inhibitors in head and neck cancers: Their roles, mechanisms and challenges
Daowen Luo, Sirinart Kumfu, Nipon Chattipakorn, Siriporn C. Chattipakorn
Biochemical Pharmacology.2025; 235: 116845. CrossRef
One-pot synthesis and pharmacological evaluation of new quinoline/pyrimido-diazepines as pulmonary antifibrotic agents
Michael Atef Fawzy, Karim Hagag Ibrahim, Ashraf A Aly, Asmaa H Mohamed, Sara Mohamed Naguib Abdel Hafez, Walaa Yehia Abdelzaher, Eslam B Elkaeed, Aisha A Alsfouk, El-Shimaa MN Abdelhafez
Future Medicinal Chemistry.2024; 16(21): 2211. CrossRef
Critical review of the current and future prospects of VEGF-TKIs in the management of squamous cell carcinoma of head and neck
Prashant Puttagunta, Saagar V. Pamulapati, James E. Bates, Jennifer H. Gross, William A. Stokes, Nicole C. Schmitt, Conor Steuer, Yong Teng, Nabil F. Saba
Frontiers in Oncology.2023;[Epub] CrossRef

4,357 View
295 Download
3 Web of Science
3 Crossref

General

A Multicenter, Prospective, Observational Study to Evaluate Ethanol-Induced Symptoms in Patients Receiving Docetaxel Chemotherapy: Young-Woong Won, Jin-Hyoung Kang, Jung Hye Kwon, Dong-Hoe Koo, Jung Hun Kang, Chi Hoon Maeng, Hee Kyung Ahn, Sung Yong Oh, Dae-Won Lee, Joohyuk Sohn, So Yeon Oh, Kyung Hee Lee, Su-Jin Koh, Keun Seok Lee, Chan-Kyu Kim, Ji-Yeon Kim, Jun Ho Ji, Sung-Bae Kim, Joo Young Ha, Ho Young Kim; Cancer Res Treat. 2023;55(4):1096-1103. Published online April 7, 2023; DOI: https://doi.org/10.4143/crt.2022.1565

Abstract PDF Supplementary Material PubReader ePub

Purpose
Several previous studies and case reports have reported ethanol-induced symptoms in patients receiving anticancer drugs containing ethanol. Most docetaxel formulations contain ethanol as a solvent. However, there are insufficient data on ethanol-induced symptoms when docetaxel-containing ethanol is administered. The primary purpose of this study was to investigate the frequency and pattern of ethanol-induced symptoms during and after docetaxel administration. The secondary purpose was to explore the risk factors for ethanol-induced symptoms.
Materials and Methods
This was a prospective, multicenter, observational study. The participants filled out ethanol-induced symptom questionnaire on the day of chemotherapy and the following day.
Results
Data from 451 patients were analyzed. The overall occurrence rate of ethanol-induced symptoms was 44.3% (200/451 patients). The occurrence rate of facial flushing was highest at 19.7% (89/451 patients), followed by nausea in 18.2% (82/451 patients), and dizziness in 17.5% (79/451 patients). Although infrequent, unsteady walking and impaired balance occurred in 4.2% and 3.3% of patients, respectively. Female sex, presence of underlying disease, younger age, docetaxel dose, and docetaxel-containing ethanol amount were significantly associated with the occurrence of ethanol-induced symptoms.
Conclusion
The occurrence of ethanol-induced symptoms was not low in patients receiving docetaxel-containing ethanol. Physicians need to pay more attention to the occurrence of ethanol-induced symptoms and prescribe ethanol-free or low-ethanol-containing formulations to high-risk patients.

Citations

Citations to this article as recorded by

Ethanol intoxication in paediatric patients receiving intravenous etoposide as conditioning regimen for allogenic hematopoietic stem cell transplant
Pauline Claraz, Marie de Tersant, Valentine Feyants, Julie Roupret-Serzec, Thomas Storme, Jean-Hugues Dalle
Journal of Oncology Pharmacy Practice.2025;[Epub] CrossRef
Evaluation of self-assembling properties of paclitaxel-biotin conjugates
Dmitry V. Beigulenko, Anna Yu. Belyaeva, Ekaterina S. Kazakova, Maria M. Antonova, Aleksander S. Peregudov, Aleksey A. Nikitin, Tatyana S. Kovshova, Yulia V. Ermolenko, Konstantin A. Kochetkov
Nano-Structures & Nano-Objects.2024; 40: 101375. CrossRef

3,839 View
221 Download
1 Web of Science
2 Crossref

ERRATUM: Recommendations for the Use of Next-Generation Sequencing and the Molecular Tumor Board for Patients with Advanced Cancer: A Report from KSMO and KCSG Precision Medicine Networking Group: Shinkyo Yoon, Miso Kim, Yong Sang Hong, Han Sang Kim, Seung Tae Kim, Jihun Kim, Hongseok Yun, Changhoon Yoo, Hee Kyung Ahn, Hyo Song Kim, In Hee Lee, In-Ho Kim, Inkeun Park, Jae Ho Jeong, Jaekyung Cheon, Jin Won Kim, Jina Yun, Sun Min Lim, Yongjun Cha, Se Jin Jang, Dae Young Zang, Tae Won Kim, Jin Hyoung Kang, Jee Hyun Kim; Cancer Res Treat. 2023;55(3):1061-1061. Published online April 21, 2023; DOI: https://doi.org/10.4143/crt.2021.1115.E; Corrects: Cancer Res Treat 2022;54(1):1

PDF PubReader ePub

Citations

Citations to this article as recorded by

Real-World Data: Implementation and Outcomes of Next-Generation Sequencing in the MENA Region
Rami Mahfouz, Reine Abou Zeidane, Tasnim Diab, Ali Tarhini, Eman Sbaity, Houry Kazarian, Yomna El Zibaoui, Nour Sabiha Naji, Mounir Barake, Hazem I. Assi
Diagnostics.2025; 15(10): 1183. CrossRef

3,031 View
115 Download
1 Crossref

Head and Neck cancer

Induction Chemotherapy as a Prognostication Index and Guidance for Treatment of Locally Advanced Head and Neck Squamous Cell Carcinoma: The Concept of Chemo-Selection (KCSG HN13-01): Yun-Gyoo Lee, Eun Joo Kang, Bhumsuk Keam, Jin-Hyuk Choi, Jin-Soo Kim, Keon Uk Park, Kyoung Eun Lee, Hyo Jung Kim, Keun-Wook Lee, Min Kyoung Kim, Hee Kyung Ahn, Seong Hoon Shin, Hye Ryun Kim, Sung-Bae Kim, Hwan Jung Yun; Cancer Res Treat. 2022;54(1):109-117. Published online April 27, 2021; DOI: https://doi.org/10.4143/crt.2020.1329

Abstract PDF PubReader ePub

Purpose
Certain patient subgroups who do not respond to induction chemotherapy (IC) show inherent chemoresistance in locally advanced head and neck squamous cell carcinoma (LA-HNSCC). This study aimed to assess the prognostic value of IC, and role of IC in guiding the selection of a definitive locoregional therapy.
Materials and Methods
Out of the 445 patients in multi-institutional LA-HNSCC cohort, 158 (36%) receiving IC were enrolled. The study outcome was to assess overall survival (OS) through IC responsiveness and its role to select subsequent treatments.
Results
Among 135 patients who completed subsequent treatment following IC, 74% responded to IC (complete response in 17% and partial response in 58%). IC-non-responders showed 4.5 times higher risk of mortality than IC-responders (hazard ratio, 4.52; 95% confidence interval, 2.32 to 8.81; p < 0.001). Among IC-responders, 84% subsequently received definitive concurrent chemoradiotherapy (CCRT) and OS was not differed by surgery or CCRT (p=0.960). Regarding IC-non-responders, 54% received CCRT and 46% underwent surgery, and OS was poor in CCRT (24-month survival rate of 38%) or surgery (24-month survival rate of 63%).
Conclusion
Response to IC is a favorable prognostic factor. For IC-responders, either surgery or CCRT achieved similar survival probabilities. For IC-non-responder, multidisciplinary approach was warranted reflecting patients’ preference, morbidity, and prognosis.

Citations

Citations to this article as recorded by

Circulating tumor DNA determines induction chemotherapy response in HPV associated oropharyngeal squamous cell carcinoma: A pilot study
Zachary M. Huttinger, Emile Gogineni, Sujith Baliga, Dukagjin M. Blakaj, Priyanka Bhateja, Marcelo Bonomi, Stephen Y. Kang, Matthew O. Old, Nolan B. Seim, Kyle K. VanKoevering, Amit Agrawal, Enver Ozer, James W. Rocco, Catherine T. Haring
Oral Oncology.2025; 161: 107179. CrossRef
Clinical decision pathway and management of locally advanced head and neck squamous cell carcinoma: A multidisciplinary consensus in Asia-Pacific
Ye Guo, Torahiko Nakashima, Byoung Chul Cho, Darren W.-T. Lim, Muh-Hwa Yang, Pei-Jen Lou, June Corry, Jin Ching Lin, Guo Pei Zhu, Kyung Hwan Kim, Bin Zhang, Zhiming Li, Ruey-Long Hong, Junice Yi Siu Ng, Ee Min Tan, Yan Ping Liu, Con Stylianou, Carmel Spit
Oral Oncology.2024; 148: 106657. CrossRef
Neoadjuvant programmed cell death 1 blockade combined with chemotherapy for locally advanced head and neck squamous cell carcinoma
Ping Han, Faya Liang, Pan Song, Taowei Wu, Yangyang Li, Ming Gao, Peiliang Lin, Jianming Fan, Xiaoming Huang
Holistic Integrative Oncology.2024;[Epub] CrossRef
Clinical prognostic factors to guide treatment strategy for HPV‑positive oropharyngeal cancer using treatment outcomes of induction chemotherapy: A real‑world experience
Hyun Bang, Hyeon-Jong Kim, Seung Lee, Hyun Shim, Jun Hwang, Woo Bae, Ik-Joo Chung, Sang-Hee Cho
Oncology Letters.2024;[Epub] CrossRef
Role of induction chemotherapy in advanced‐stage olfactory neuroblastoma
Sung‐Woo Cho, Bhumsuk Keam, Keun‐Wook Lee, Ji‐Won Kim, Doo Hee Han, Hyun Jik Kim, Jeong‐Whun Kim, Dong‐Young Kim, Chae‐Seo Rhee, Yun Jung Bae, Ji‐Hoon Kim, Keun‐Yong Eom, Hong‐Gyun Wu, Yong Hwy Kim, Chae‐Yong Kim, Sun Ha Paek, Hyojin Kim, Tae‐Bin Won
International Forum of Allergy & Rhinology.2024; 14(12): 1882. CrossRef
Intra-Arterial Chemotherapy for Locally Advanced Oral Cavity Cancer
B. B. Vyzhigina, M. A. Kropotov, B. I. Dolgushin, D. A. Safarov, I. V. Pogrebnyakov, S. B. Alieva
Journal of oncology: diagnostic radiology and radiotherapy.2024; 7(3): 62. CrossRef
Response to induction chemotherapy as a prognostic indicator in locally advanced head and neck squamous cell carcinoma
Francesca Huwyler, Roland Giger, Ruben Bill, Daniel Rauch, Simon Haefliger
Journal of Cancer Research and Clinical Oncology.2024;[Epub] CrossRef
Response to induction chemotherapy in sinonasal malignancies: A single‐institutional experience
Sarah C. Nyirjesy, Rachel Fenberg, Margaret A. Heller, Ryan T. Judd, Michael M. Li, Brandon Koch, Marcelo Bonomi, Ricardo L. Carrau, Kyle K. VanKoevering
Head & Neck.2023; 45(6): 1445. CrossRef
Human Papillomavirus-Related Non-Metastatic Oropharyngeal Carcinoma: Current Local Treatment Options and Future Perspectives
Michaela Svajdova, Pavol Dubinsky, Tomas Kazda, Branislav Jeremic
Cancers.2022; 14(21): 5385. CrossRef

7,782 View
237 Download
7 Web of Science
9 Crossref

Recommendations for the Use of Next-Generation Sequencing and the Molecular Tumor Board for Patients with Advanced Cancer: A Report from KSMO and KCSG Precision Medicine Networking Group: Shinkyo Yoon, Miso Kim, Yong Sang Hong, Han Sang Kim, Seung Tae Kim, Jihun Kim, Hongseok Yun, Changhoon Yoo, Hee Kyung Ahn, Hyo Song Kim, In Hee Lee, In-Ho Kim, Inkeun Park, Jae Ho Jeong, Jaekyung Cheon, Jin Won Kim, Jina Yun, Sun Min Lim, Yongjun Cha, Se Jin Jang, Dae Young Zang, Tae Won Kim, Jin Hyoung Kang, Jee Hyun Kim; Cancer Res Treat. 2022;54(1):1-9. Published online December 13, 2021; DOI: https://doi.org/10.4143/crt.2021.1115; Correction in: Cancer Res Treat 2023;55(3):1061

Abstract PDF PubReader ePub

Next-generation sequencing (NGS) is becoming essential in the fields of precision oncology. With implementation of NGS in daily clinic, the needs for continued education, facilitated interpretation of NGS results and optimal treatment delivery based on NGS results have been addressed. Molecular tumor board (MTB) is multidisciplinary approach to keep pace with the growing knowledge of complex molecular alterations in patients with advanced solid cancer. Although guidelines for NGS use and MTB have been developed in western countries, there is limitation for reflection of Korea’s public health environment and daily clinical practice. These recommendations provide a critical guidance from NGS panel testing to final treatment decision based on MTB discussion.

Citations

Citations to this article as recorded by

Clinical implementation of next-generation sequencing testing and genomically-matched therapy: a real-world data in a tertiary hospital
Jin Won Kim, Hee Young Na, Sejoon Lee, Ji-Won Kim, Koung Jin Suh, Se Hyun Kim, Yu Jung Kim, Keun-Wook Lee, Jong Seok Lee, Jaihwan Kim, Jin-Hyeok Hwang, Kihwan Hwang, Chae-Yong Kim, Yong Beom Kim, Soomin Ahn, Kyu Sang Lee, Hyojin Kim, Hye Seung Lee, So Yeo
Scientific Reports.2025;[Epub] CrossRef
Expert Consensus on Molecular Tumor Boards in Taiwan: Joint Position Paper by the Taiwan Oncology Society and the Taiwan Society of Pathology
Ming-Huang Chen, Wan-Shan Li, Bin-Chi Liao, Chiao-En Wu, Chien-Feng Li, Chia-Hsun Hsieh, Feng-Che Kuan, Huey-En Tzeng, Jen-Fan Hang, Nai-Jung Chiang, Tse-Ching Chen, Tom Wei-Wu Chen, John Wen-Cheng Chang, Yao-Yu Hsieh, Yen-Lin Chen, Yi-Chen Yeh, Yi-Hsin L
Journal of Cancer Research and Practice.2024;[Epub] CrossRef
Pragmatic nationwide master observational trial based on genomic alterations in advanced solid tumors: KOrean Precision Medicine Networking Group Study of MOlecular profiling guided therapy based on genomic alterations in advanced Solid tumors (KOSMOS)-II
Sun Young Kim, Jee Hyun Kim, Tae-Yong Kim, Sook Ryun Park, Shinkyo Yoon, Soohyeon Lee, Se-Hoon Lee, Tae Min Kim, Sae-Won Han, Hye Ryun Kim, Hongseok Yun, Sejoon Lee, Jihun Kim, Yoon-La Choi, Kui Son Choi, Heejung Chae, Hyewon Ryu, Gyeong-Won Lee, Dae Youn
BMC Cancer.2024;[Epub] CrossRef
Combining germline, tissue and liquid biopsy analysis by comprehensive genomic profiling to improve the yield of actionable variants in a real-world cancer cohort
I. Vanni, L. Pastorino, V. Andreotti, D. Comandini, G. Fornarini, M. Grassi, A. Puccini, E. T. Tanda, A. Pastorino, V. Martelli, L. Mastracci, F. Grillo, F. Cabiddu, A. Guadagno, S. Coco, E. Allavena, F. Barbero, W. Bruno, B. Dalmasso, S. E. Bellomo, C. M
Journal of Translational Medicine.2024;[Epub] CrossRef
Clinical practice recommendations for the use of next-generation sequencing in patients with solid cancer: a joint report from KSMO and KSP
Miso Kim, Hyo Sup Shim, Sheehyun Kim, In Hee Lee, Jihun Kim, Shinkyo Yoon, Hyung-Don Kim, Inkeun Park, Jae Ho Jeong, Changhoon Yoo, Jaekyung Cheon, In-Ho Kim, Jieun Lee, Sook Hee Hong, Sehhoon Park, Hyun Ae Jung, Jin Won Kim, Han Jo Kim, Yongjun Cha, Sun
Journal of Pathology and Translational Medicine.2024; 58(4): 147. CrossRef
Clinical Practice Recommendations for the Use of Next-Generation Sequencing in Patients with Solid Cancer: A Joint Report from KSMO and KSP
Miso Kim, Hyo Sup Shim, Sheehyun Kim, In Hee Lee, Jihun Kim, Shinkyo Yoon, Hyung-Don Kim, Inkeun Park, Jae Ho Jeong, Changhoon Yoo, Jaekyung Cheon, In-Ho Kim, Jieun Lee, Sook Hee Hong, Sehhoon Park, Hyun Ae Jung, Jin Won Kim, Han Jo Kim, Yongjun Cha, Sun
Cancer Research and Treatment.2024; 56(3): 721. CrossRef
Nationwide precision oncology pilot study: KOrean Precision Medicine Networking Group Study of MOlecular profiling-guided therapy based on genomic alterations in advanced solid tumors (KOSMOS) KCSG AL-20-05
T.-Y. Kim, S.Y. Kim, J.H. Kim, H.A. Jung, Y.J. Choi, I.G. Hwang, Y. Cha, G.-W. Lee, Y.-G. Lee, T.M. Kim, S.-H. Lee, S. Lee, H. Yun, Y.L. Choi, S. Yoon, S.W. Han, T.-Y. Kim, T.W. Kim, D.Y. Zang, J.H. Kang
ESMO Open.2024; 9(10): 103709. CrossRef
Utilizing Plasma Circulating Tumor DNA Sequencing for Precision Medicine in the Management of Solid Cancers
Yongjun Cha, Sheehyun Kim, Sae-Won Han
Cancer Research and Treatment.2023; 55(2): 367. CrossRef
Mutational evolution after chemotherapy‐progression in metastatic colorectal cancer revealed by circulating tumor DNA analysis
Sheehyun Kim, Yongjun Cha, Yoojoo Lim, Hanseong Roh, Jun‐Kyu Kang, Kyung‐Hun Lee, Min Jung Kim, Ji Won Park, Seung‐Bum Ryoo, Hwang‐Phill Kim, Seung‐Yong Jeong, Kyu Joo Park, Sae‐Won Han, Tae‐You Kim
International Journal of Cancer.2023; 153(3): 571. CrossRef
Establishing molecular pathology curriculum for pathology trainees and continued medical education: a collaborative work from the Molecular Pathology Study Group of the Korean Society of Pathologists
Jiwon Koh, Ha Young Park, Jeong Mo Bae, Jun Kang, Uiju Cho, Seung Eun Lee, Haeyoun Kang, Min Eui Hong, Jae Kyung Won, Youn-La Choi, Wan-Seop Kim, Ahwon Lee
Journal of Pathology and Translational Medicine.2023; 57(5): 265. CrossRef
Implementation of Precision Oncology in the National Healthcare System: A Statement Proposal Endorsed by Italian Scientific Societies
Gianpiero Fasola, Maria C. Barducci, Valeria D. Tozzi, Luigi Cavanna, Saverio Cinieri, Francesco Perrone, Carmine Pinto, Antonio Russo, Anna Sapino, Francesco Grossi, Giuseppe Aprile
JCO Precision Oncology.2023;[Epub] CrossRef
Development of two 410-cancer-gene panel tests for solid tumors and liquid biopsy based on genome data of 5,143 Japanese cancer patients
Yuji SHIMODA, Takeshi NAGASHIMA, Kenichi URAKAMI, Fukumi KAMADA, Sou NAKATANI, Maki MIZUGUCHI, Masakuni SERIZAWA, Keiichi HATAKEYAMA, Keiichi OHSHIMA, Tohru MOCHIZUKI, Sumiko OHNAMI, Shumpei OHNAMI, Takeshi KAWAKAMI, Kentaro YAMAZAKI, Haruyasu MURAKAMI, H
Biomedical Research.2022; 43(4): 115. CrossRef
Clinical Implication of Molecular Tumor Board
Soohyeon Lee
The Korean Journal of Medicine.2022; 97(5): 319. CrossRef
Somatic Mutations of TP53 Identified by Targeted Next-Generation Sequencing Are Poor Prognostic Factors for Primary Operable Breast Cancer: A Single-Center Study
Jung Ho Park, Mi Jung Kwon, Jinwon Seo, Ho Young Kim, Soo Kee Min, Lee Su Kim
Journal of Breast Cancer.2022; 25(5): 379. CrossRef

10,836 View
543 Download
14 Web of Science
14 Crossref

Head and Neck Cancer

Recent Treatment Patterns of Oropharyngeal Cancer in Korea Based on the Expert Questionnaire Survey of the Korean Society for Head and Neck Oncology (KSHNO): Kyu Hye Choi, Jin Ho Song, Yeon-Sil Kim, Ji-hoon Kim, Woo-Jin Jeong, Inn-Chul Nam, Jin Ho Kim, Hee Kyung Ahn, Sang Hoon Chun, Hyun Jun Hong, Young-Hoon Joo, Young-Gyu Eun, Sung Ho Moon, Jeongshim Lee; Cancer Res Treat. 2021;53(4):1004-1014. Published online January 29, 2021; DOI: https://doi.org/10.4143/crt.2020.973

Abstract PDF Supplementary Material PubReader ePub

Purpose
The incidence of human papillomavirus (HPV)-related oropharyngeal cancer (OPC) has increased, and staging and optimal therapeutic approaches are challenging. A questionnaire survey was conducted to investigate the controversial treatment policy of stage T2 OPC according to the N category and determine the opinions of multidisciplinary experts in Korea.
Materials and Methods
Five OPC scenarios were developed by the Subcommittee on Oropharyngeal Treatment Guidelines of the Korean Society for Head and Neck Oncology and distributed to experts of multidisciplinary treatment hospitals.
Results
Sixty-five experts from 45 institutions responded. For the HPV-positive T2N0M0 scenario, 67.7% of respondents selected surgery followed by definitive concurrent chemoradiotherapy (CCRT) or radiotherapy alone. For the T2N1M0 HPV-positive scenario, there was a notable difference in the selection of primary treatment by expert specialty; 53.9% of respondents selected surgery and 39.8% selected definitive CCRT as the primary treatment. For the T2N3M0 advanced HPV-positive scenario, 50.0% of respondents selected CCRT and 33.3% considered induction chemotherapy (IC) as the primary treatment. CCRT and IC were significantly more frequently selected for the HPV-related OPC cases (p=0.010). The interdepartmental variability showed that the head and neck surgeons and medical oncologists favored surgery, whereas the radiation oncologists preferably selected definitive CCRT (p < 0.001).
Conclusion
In this study, surgery was preferred for lymph node-negative OPC, and as lymph node metastasis progressed, CCRT tended to be preferred, and IC was administered. Clinical practice patterns by stage and HPV status showed differences according to expert specialty. Multidisciplinary consensus guidelines will be essential in the future.

Citations

Citations to this article as recorded by

Controversies in Lung Cancer: Heterogeneity in Treatment Recommendations for Stage III NSCLC According to Disease Burden and Oncogenic Driver Alterations
Jeremy P Harris, Dylann K Fujimoto, Misako Nagasaka, Eric Ku, Garrett Harada, Hari Keshava, Ali Mahtabifard, Javier Longoria, Niral Patel, Steven Seyedin, Aaron Simon, Allen Chen
Clinical Lung Cancer.2022; 23(4): 333. CrossRef
Survey of radiation field and dose in human papillomavirus-positive oropharyngeal cancer: is de-escalation actually applied in clinical practice?
Kyu Hye Choi, Jin Ho Song, Yeon-Sil Kim, Sung Ho Moon, Jeongshim Lee, Young-Taek Oh, Dongryul Oh, Jin Ho Kim, Jun Won Kim
Radiation Oncology Journal.2021; 39(3): 174. CrossRef

6,680 View
159 Download
3 Web of Science
2 Crossref

Breast Cancer

Implications of Tamoxifen Resistance in Palbociclib Efficacy for Patients with Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer: Subgroup Analyses of KCSG-BR15-10 (YoungPEARL): Jiyun Lee, Seock-Ah Im, Gun Min Kim, Kyung Hae Jung, Seok Yun Kang, In Hae Park, Jee Hyun Kim, Hee Kyung Ahn, Yeon Hee Park; Cancer Res Treat. 2021;53(3):695-702. Published online December 17, 2020; DOI: https://doi.org/10.4143/crt.2020.1246

Abstract PDF PubReader ePub

Purpose
YoungPEARL (KCSG-BR15-10) trial demonstrated a significant progression-free survival (PFS) benefit for premenopausal patients with hormone receptor–positive/human epidermal growth factor receptor 2–negative (HR+/HER2–) metastatic breast cancer (MBC) for palbociclib plus exemestane with ovarian function suppression compared to capecitabine. However, the number of tamoxifen-sensitive premenopausal patients was small because most recurrences occurred early during adjuvant endocrine therapy (ET), with tamoxifen being the only drug used; hence, the data for these patients were limited. Here we present a subgroup analysis according to tamoxifen sensitivity from the YoungPEARL study. Materials and Methods Patients were randomized 1:1 to receive palbociclib+ET (oral exemestane 25 mg/day for 28 days, palbociclib 125 mg/day for 21 days, plus leuprolide 3.75 mg subcutaneously every 4 weeks) or chemotherapy (oral capecitabine 1,250 mg/m2 twice daily for 14 days every 3 weeks). Tamoxifen resistance was defined as: relapse while on adjuvant tamoxifen, relapse within 12 months of completing adjuvant tamoxifen, or progression while on first-line tamoxifen within 6 months for MBC.
Results
In total, 184 patients were randomized and 178 were included in the modified intention-to-treat population. PFS improvement in the palbociclib+ET group was observed in tamoxifen-sensitive patients (hazard ratio, 0.38; 95% confidence interval, 0.12 to 1.19). Furthermore, palbociclib+ET prolonged median PFS compared with capecitabine in tamoxifen-sensitive (20.5 months vs. 12.6 months) and tamoxifen-resistant (20.1 months vs. 14.5 months) patients. Palbociclib+ET demonstrated a higher rate of objective response, disease control, and clinical benefit in tamoxifen-sensitive patients. Conclusion This post hoc exploratory analysis suggests that palbociclib+ET is a promising therapeutic option for premenopausal HR+/HER2– MBC patients irrespective of tamoxifen sensitivity.

Citations

Citations to this article as recorded by

Palbociclib plus endocrine therapy in hormone receptor-positive and HER2 negative metastatic breast cancer: a multicenter real-world study in the northwest of China
Jiao Yang, Bing Zhao, Xiaoling Ling, Donghui Li, Jiuda Zhao, Yonggang Lv, Guangxi Wang, Xinlan Liu, Nanlin Li, Jin Yang
BMC Cancer.2023;[Epub] CrossRef

7,497 View
278 Download
2 Web of Science
1 Crossref

Feasibility Study of Physician Orders for Life-Sustaining Treatment for Patients with Terminal Cancer: Ho Jung An, Hyun Jeong Jeon, Sang Hoon Chun, Hyun Ae Jung, Hee Kyung Ahn, Kyung Hee Lee, Min-ho Kim, Ju Hee Kim, Jaekyung Cheon, JinShil Kim, Su-Jin Koh; Cancer Res Treat. 2019;51(4):1632-1638. Published online April 18, 2019; DOI: https://doi.org/10.4143/crt.2019.009

Abstract PDF PubReader ePub

Purpose
Physician Orders for Life-Sustaining Treatment (POLST) form is a legal document for terminally ill patients to make medical decisions with physicians near the end-of-life. A multicenter prospective study was conducted to evaluate the feasibility of POLST administration in actual oncological practice.
Materials and Methods
Patients with terminal cancer, age ≥ 20 years, and capable of communicating were eligible. The primary endpoint was the completion rate of POLST. Data about physicians’ or patients’ barriers were also collected.
Results
From June to December 2017, 336 patients from seven hospitals were eligible. Median patient age was 66 years (range, 20 to 94 years); 52.7% were male; and 60.4% had poor performance status. Primary cancer sites were hepato-pancreato-biliary (26.2%), lung (23.2%), and gastrointestinal (19.9%). Expected survival duration was 10.6±7.3 weeks, with 41.2% receiving hospice care, 37.9% showing progression after cancer treatment, and the remaining patients were under active treatment (15.8%) or initially diagnosed with terminal cancer (5.1%). POLST forms were introduced to 60.1% of patients, and 31.3% signed the form. Physicians’ barriers were reluctance of family (49.7%), lack of rapport (44.8%), patients’ denial of prognosis (34.3%), lack of time (22.7%), guilty feelings (21.5%), and uncertainty about either prognosis (21.0%) or the right time to discuss POLST (16.6%). The patients’ barriers were the lack of knowledge/understanding of POLST (65.1%), emotional discomfort (63.5%), difficulty in decision-making (66.7%), or denial of prognosis (14.3%).
Conclusion
One-third of patients completed POLST forms, and various barriers were identified. To overcome such barriers, social engagement, education, and systematic support might be necessary.

Citations

Citations to this article as recorded by

Characteristics of Life-Sustaining Treatment Decisions: National Data Analysis in South Korea
Jiyeon Choi, Heejung Jeon, Ilhak Lee
Asian Bioethics Review.2024; 16(1): 33. CrossRef
An Integrative Review of the State of POLST Science: What Do We Know and Where Do We Go?
Elizabeth E. Umberfield, Matthew C. Fields, Rachel Lenko, Teryn P. Morgan, Elissa Schuler Adair, Erik K. Fromme, Hillary D. Lum, Alvin H. Moss, Neil S. Wenger, Rebecca L. Sudore, Susan E. Hickman
Journal of the American Medical Directors Association.2024; 25(4): 557. CrossRef
Experience and perspectives of end-of-life care discussion and physician orders for life-sustaining treatment of Korea (POLST-K): a cross-sectional study
Hyeon-Su Im, Insook Lee, Shinmi Kim, Jong Soo Lee, Ju-Hee Kim, Jae Young Moon, Byung Kyu Park, Kyung Hee Lee, Myung Ah Lee, Sanghoon Han, Yoonki Hong, Hyeyeoung Kim, Jaekyung Cheon, Su-Jin Koh
BMC Medical Ethics.2023;[Epub] CrossRef
Problems Related to the Act on Decisions on Life-Sustaining Treatment and Directions for Improvement
Dae Seog Heo, Shin Hye Yoo, Bhumsuk Keam, Sang Ho Yoo, Younsuck Koh
The Korean Journal of Hospice and Palliative Care.2022; 25(1): 1. CrossRef
Discussing POLST-facilitated hospice care enrollment in patients with terminal cancer
Ho Jung An, Hyun Jeong Jeon, Sang Hoon Chun, Hyun Ae Jung, Hee Kyung Ahn, Kyung Hee Lee, Min-ho Kim, Ju Hee Kim, Jaekyung Cheon, Su-Jin Koh
Supportive Care in Cancer.2022; 30(9): 7431. CrossRef
The Medical Orders for Scope of Treatment (MOST) form completion: a retrospective study
Anastasia A. Mallidou, Coby Tschanz, Elisabeth Antifeau, Kyoung Young Lee, Jenipher Kayuni Mtambo, Holly Heckl
BMC Health Services Research.2022;[Epub] CrossRef
Recommended summary plan for emergency care and treatment: ReSPECT a mixed-methods study
Gavin D Perkins, Claire A Hawkes, Karin Eli, James Griffin, Claire Jacques, Caroline J Huxley, Keith Couper, Cynthia Ochieng, Jonathan Fuld, Zoe Fritz, Rob George, Doug Gould, Richard Lilford, Martin Underwood, Catherine Baldock, Chris Bassford, Peter-Mar
Health and Social Care Delivery Research.2022; 10(40): 1. CrossRef
Emergency Healthcare Providers’ Knowledge about and Attitudes toward Advance Directives: A Cross-Sectional Study between Nurses and Emergency Medical Technicians at an Emergency Department
Sun Woo Hong, Shinmi Kim, Yu Jin Yun, Hyun Sook Jung, JaeLan Shim, JinShil Kim
International Journal of Environmental Research and Public Health.2021; 18(3): 1158. CrossRef
Difficulties Doctors Experience during Life-Sustaining Treatment Discussion after Enactment of the Life-Sustaining Treatment Decisions Act: A Cross-Sectional Study
Shin Hye Yoo, Wonho Choi, Yejin Kim, Min Sun Kim, Hye Yoon Park, Bhumsuk Keam, Dae Seog Heo
Cancer Research and Treatment.2021; 53(2): 584. CrossRef
We Want More Than Life-Sustaining Treatment during End-of-Life Care: Focus-Group Interviews
Mirinae Kim, Minju Kim
International Journal of Environmental Research and Public Health.2021; 18(9): 4415. CrossRef
Changes in decision-making process for life-sustaining treatment in patients with advanced cancer after the life-sustaining treatment decisions-making act
Hyeyeong Kim, Hyeon-Su Im, Kyong Og Lee, Young Joo Min, Jae-Cheol Jo, Yunsuk Choi, Yoo Jin Lee, Daseul Kang, Changyoung Kim, Su-Jin Koh, Jaekyung Cheon
BMC Palliative Care.2021;[Epub] CrossRef
Asian patients’ perspectives on advance care planning: A mixed-method systematic review and conceptual framework
Diah Martina, Olaf P Geerse, Cheng-Pei Lin, Martina S Kristanti, Wichor M Bramer, Masanori Mori, Ida J Korfage, Agnes van der Heide, Judith AC Rietjens, Carin CD van der Rijt
Palliative Medicine.2021; 35(10): 1776. CrossRef
Life-Sustaining Treatment States in Korean Cancer Patients after Enforcement of Act on Decisions on Life-Sustaining Treatment for Patients at the End of Life
Young-Woong Won, Hwa Jung Kim, Jung Hye Kwon, Ha Yeon Lee, Sun Kyung Baek, Yu Jung Kim, Do Yeun Kim, Hyewon Ryu
Cancer Research and Treatment.2021; 53(4): 908. CrossRef
Advance care planning in Asian culture
Shao-Yi Cheng, Cheng-Pei Lin, Helen Yue-lai Chan, Diah Martina, Masanori Mori, Sun-Hyun Kim, Raymond Ng
Japanese Journal of Clinical Oncology.2020; 50(9): 976. CrossRef
Preference and Performance Fidelity of Modified Korean Physician Order for Life-Sustaining Treatment (MK-POLST) Items in Hospice Patients with Cancer
Ji Hee Han, Hye Sook Chun, Tae Hee Kim, Rock Bum Kim, Jung Hoon Kim, Jung Hun Kang
The Korean Journal of Hospice and Palliative Care.2019; 22(4): 198. CrossRef

8,699 View
167 Download
12 Web of Science
15 Crossref

Investigating the Feasibility of Targeted Next-Generation Sequencing to Guide the Treatment of Head and Neck Squamous Cell Carcinoma: Sun Min Lim, Sang Hee Cho, In Gyu Hwang, Jae Woo Choi, Hyun Chang, Myung-Ju Ahn, Keon Uk Park, Ji-Won Kim, Yoon Ho Ko, Hee Kyung Ahn, Byoung Chul Cho, Byung-Ho Nam, Sang Hoon Chun, Ji Hyung Hong, Jung Hye Kwon, Jong Gwon Choi, Eun Joo Kang, Tak Yun, Keun-Wook Lee, Joo-Hang Kim, Jin Soo Kim, Hyun Woo Lee, Min Kyoung Kim, Dongmin Jung, Ji Eun Kim, Bhumsuk Keam, Hwan Jung Yun, Sangwoo Kim, Hye Ryun Kim; Cancer Res Treat. 2019;51(1):300-312. Published online May 9, 2018; DOI: https://doi.org/10.4143/crt.2018.012

Abstract PDF Supplementary Material PubReader ePub

Purpose
Head and neck squamous cell carcinoma (HNSCC) is a deadly disease in which precision medicine needs to be incorporated. We aimed to implement next-generation sequencing (NGS) in determining actionable targets to guide appropriate molecular targeted therapy in HNSCC patients.
Materials and Methods
Ninety-three tumors and matched blood samples underwent targeted sequencing of 244 genes using the Illumina HiSeq 2500 platform with an average depth of coverage of greater than 1,000×. Clinicopathological data from patients were obtained from 17 centers in Korea, and were analyzed in correlation with NGS data.
Results
Ninety-two of the 93 tumors were amenable to data analysis. TP53 was the most common mutation, occurring in 47 (51%) patients, followed by CDKN2A (n=23, 25%), CCND1 (n=22, 24%), and PIK3CA (n=19, 21%). The total mutational burden was similar between human papillomavirus (HPV)–negative vs. positive tumors, although TP53, CDKN2A and CCND1 gene alterations occurred more frequently in HPV-negative tumors. HPV-positive tumors were significantly associated with immune signature-related genes compared to HPV-negative tumors. Mutations of NOTCH1 (p=0.027), CDKN2A (p < 0.001), and TP53 (p=0.038) were significantly associated with poorer overall survival. FAT1 mutations were highly enriched in cisplatin responders, and potentially targetable alterations such as PIK3CA E545K and CDKN2A R58X were noted in 14 patients (15%).
Conclusion
We found several targetable genetic alterations, and our findings suggest that implementation of precision medicine in HNSCC is feasible. The predictive value of each targetable alteration should be assessed in a future umbrella trial using matched molecular targeted agents.

Citations

Citations to this article as recorded by

Personalized Biomarker-Based Umbrella Trial for Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: KCSG HN 15-16 TRIUMPH Trial
Bhumsuk Keam, Min Hee Hong, Seong Hoon Shin, Seong Gu Heo, Ji Eun Kim, Hee Kyung Ahn, Yun-Gyoo Lee, Keon-Uk Park, Tak Yun, Keun-Wook Lee, Sung-Bae Kim, Sang-Cheol Lee, Min Kyoung Kim, Sang Hee Cho, So Yeon Oh, Sang-Gon Park, Shinwon Hwang, Byung-Ho Nam, S
Journal of Clinical Oncology.2024; 42(5): 507. CrossRef
A Phase II Trial of Nintedanib in Patients with Metastatic or Recurrent Head and Neck Squamous Cell Carcinoma: In-Depth Analysis of Nintedanib Arm from the KCSG HN 15-16 TRIUMPH Trial
Kyoo Hyun Kim, Sun Min Lim, Hee Kyung Ahn, Yun-Gyoo Lee, Keun-Wook Lee, Myung-Ju Ahn, Bhumsuk Keam, Hye Ryun Kim, Hyun Woo Lee, Ho Jung An, Jin-Soo Kim
Cancer Research and Treatment.2024; 56(1): 37. CrossRef
Extracellular vesicles as tools and targets in therapy for diseases
Mudasir A. Kumar, Sadaf K. Baba, Hana Q. Sadida, Sara Al. Marzooqi, Jayakumar Jerobin, Faisal H. Altemani, Naseh Algehainy, Mohammad A. Alanazi, Abdul-Badi Abou-Samra, Rakesh Kumar, Ammira S. Al-Shabeeb Akil, Muzafar A. Macha, Rashid Mir, Ajaz A. Bhat
Signal Transduction and Targeted Therapy.2024;[Epub] CrossRef
Impact of PIK3CA and cell cycle pathway genetic alterations on durvalumab efficacy in patients with head and neck squamous cell carcinoma: Post hoc analysis of TRIUMPH study
Dong Hyun Kim, Seung Taek Lim, Hye Ryun Kim, Eun Joo Kang, Hee Kyung Ahn, Yun-Gyoo Lee, Der Sheng Sun, Jung Hye Kwon, Sang-Cheol Lee, Hyun Woo Lee, Min Kyoung Kim, Bhumsuk Keam, Keon-Uk Park, Seong-Hoon Shin, Hwan Jung Yun
Oral Oncology.2024; 151: 106739. CrossRef
Characterization of macrophages in head and neck squamous cell carcinoma and development of MRG-based risk signature
Lei Liu, Qiang Liu
Scientific Reports.2024;[Epub] CrossRef
The Next Chapter in Cancer Diagnostics: Advances in HPV-Positive Head and Neck Cancer
Antea Krsek, Lara Baticic, Tamara Braut, Vlatka Sotosek
Biomolecules.2024; 14(8): 925. CrossRef
Biomarkers in head and neck squamous cell carcinoma: unraveling the path to precision immunotherapy
Kamal S. Saini, Sasikala Somara, Heidi C. Ko, Purva Thatai, Angela Quintana, Zachary D. Wallen, Michelle F. Green, Ravi Mehrotra, Sandra McGuigan, Lingjuan Pang, Soma Das, Kavita Yadav, Dobrica Neric, Luca Cantini, Chinmayee Joshi, Kazuya Iwamoto, Sudha D
Frontiers in Oncology.2024;[Epub] CrossRef
Massive parallel sequencing of head and neck conventional squamous cell carcinomas: A comprehensive review
Alfons Nadal, Antonio Cardesa, Abbas Agaimy, Alhadi Almangush, Alessandro Franchi, Henrik Hellquist, Ilmo Leivo, Nina Zidar, Alfio Ferlito
Virchows Archiv.2024; 485(6): 965. CrossRef
FAT1 expression in T-cell acute lymphoblastic leukemia (T-ALL) modulates proliferation and WNT signaling
Sven Liebig, Martin Neumann, Patricia Silva, Jutta Ortiz-Tanchez, Veronika Schulze, Konstandina Isaakidis, Cornelia Schlee, Michael P. Schroeder, Thomas Beder, Luc G. T. Morris, Timothy A. Chan, Lorenz Bastian, Thomas Burmeister, Stefan Schwartz, Nicola G
Scientific Reports.2023;[Epub] CrossRef
Short-term immune-checkpoint inhibition partially rescues perturbed bone marrow hematopoiesis in mismatch-repair deficient tumors
Paula Krone, Annabell Wolff, Julia Teichmann, Johanna Maennicke, Julia Henne, Leonie Engster, Inken Salewski, Wendy Bergmann, Christian Junghanss, Claudia Maletzki
OncoImmunology.2023;[Epub] CrossRef
Genetic Mutations Associated with Inflammatory Response Caused by HPV Integration in Oropharyngeal Squamous Cell Carcinoma
Mai Atique, Isis Muniz, Fatemeh Farshadi, Michael Hier, Alex Mlynarek, Marco Macarella, Mariana Maschietto, Belinda Nicolau, Moulay A. Alaoui-Jamali, Sabrina Daniela da Silva
Biomedicines.2023; 12(1): 24. CrossRef
New Treatment Development for Larynx Preservation
Susumu Okano
Koutou (THE LARYNX JAPAN).2023; 35(2): 98. CrossRef
Current Trends in Precision Medicine and Next-Generation Sequencing in Head and Neck Cancer
Roberto N. Solis, Dustin A. Silverman, Andrew C. Birkeland
Current Treatment Options in Oncology.2022; 23(2): 254. CrossRef
EGFR Mutation and 11q13 Amplification Are Potential Predictive Biomarkers for Immunotherapy in Head and Neck Squamous Cell Carcinoma
Shengjin Dou, Lin Zhang, Chong Wang, Yanli Yao, Wen Jiang, Lulu Ye, Jiang Li, Sicheng Wu, Debin Sun, Xiaoli Gong, Rongrong Li, Guopei Zhu
Frontiers in Immunology.2022;[Epub] CrossRef
Diagnostics of HNSCC Patients: An Analysis of Cell Lines and Patient-Derived Xenograft Models for Personalized Therapeutical Medicine
Ramona Gabriela Ursu, Ionut Luchian, Costin Damian, Elena Porumb-Andrese, Nicolae Ghetu, Roxana Gabriela Cobzaru, Catalina Lunca, Carmen Ripa, Diana Costin, Igor Jelihovschi, Florin Dumitru Petrariu, Luminita Smaranda Iancu
Diagnostics.2022; 12(5): 1071. CrossRef
Unraveling most abundant mutational signatures in head and neck cancer
Michaela Plath, Johanna Gass, Mario Hlevnjak, Qiaoli Li, Bohai Feng, Xavier Pastor Hostench, Matthias Bieg, Lea Schroeder, Dana Holzinger, Marc Zapatka, Kolja Freier, Wilko Weichert, Jochen Hess, Karim Zaoui
International Journal of Cancer.2021; 148(1): 115. CrossRef
Worldwide prevalence of PI3K-AKT-mTOR pathway mutations in head and neck cancer: A systematic review and meta-analysis
Adriana Castelo de Moura, Daniele Xavier Assad, Juliana Amorim dos Santos, Isabela Porto de Toledo, Gustavo Barcelos Barra, Rogerio Moraes Castilho, Cristiane Helena Squarize, Eliete Neves Silva Guerra
Critical Reviews in Oncology/Hematology.2021; 160: 103284. CrossRef
Immuno-Oncological Biomarkers for Squamous Cell Cancer of the Head and Neck: Current State of the Art and Future Perspectives
Stijn J. De Keukeleire, Tijl Vermassen, Elien Hilgert, David Creytens, Liesbeth Ferdinande, Sylvie Rottey
Cancers.2021; 13(7): 1714. CrossRef
Comprehensive Analysis of Mutation-Based and Expressed Genes-Based Pathways in Head and Neck Squamous Cell Carcinoma
Bhumsuk Keam, Jin-Young Park, Jin-Pyo Kim, Gun-Do Kim, Yun-Suk Yu, Sang-Hee Cho, Sangwoo Kim, Hee-Kyung Ahn, Sang-Hoon Chun, Jung-Hye Kwon, Tak Yun, Ji-Won Kim, Ji-Eun Kim, Myung-Ju Ahn, Joo-Hang Kim, Hwan-Jung Yun
Processes.2021; 9(5): 792. CrossRef
Prognostic and Predictive Factors in Advanced Head and Neck Squamous Cell Carcinoma
Teresa Magnes, Sandro Wagner, Dominik Kiem, Lukas Weiss, Gabriel Rinnerthaler, Richard Greil, Thomas Melchardt
International Journal of Molecular Sciences.2021; 22(9): 4981. CrossRef
A phase II study of poziotinib in patients with recurrent and/or metastatic head and neck squamous cell carcinoma
Ji Hyun Lee, Seong Gu Heo, Beung‐Chul Ahn, Min Hee Hong, Byoung Chul Cho, Sun Min Lim, Hye Ryun Kim
Cancer Medicine.2021; 10(20): 7012. CrossRef
Therapeutic implications of activating noncanonical PIK3CA mutations in head and neck squamous cell carcinoma
Nan Jin, Bhumsuk Keam, Janice Cho, Michelle J. Lee, Hye Ryun Kim, Hayarpi Torosyan, Natalia Jura, Patrick K.S. Ng, Gordon B. Mills, Hua Li, Yan Zeng, Zohar Barbash, Gabi Tarcic, Hyunseok Kang, Julie E. Bauman, Mi-Ok Kim, Nathan K. VanLandingham, Danielle
Journal of Clinical Investigation.2021;[Epub] CrossRef
Understanding the Pattern of Oropharyngeal Cancers from North-East Romanian Patients
Ramona Ursu, Simona Giusca, Irene Spiridon, Bianca Manole, Mihai Danciu, Victor Costan, Dragos Palade, Nicolae Ghetu, Paula Toader, Mădălina Vlad, Costin Damian, Elena Porumb-Andrese, Ionut Luchian, Luminița Iancu
Applied Sciences.2021; 11(24): 12079. CrossRef
Immunologic and immunogenomic aspects of tumor progression
Andrea Ladányi, József Tímár
Seminars in Cancer Biology.2020; 60: 249. CrossRef
Prospective assessment of the clinical benefit of a tailored cancer gene set built on a next-generation sequencing platform in patients with recurrent or metastatic head and neck cancer
Thomas C. Westbrook, Ian S. Hagemann, Jessica Ley, Kevin Chen, Kevin Palka, Jingxia Liu, Ling Chen, Peter Oppelt, Douglas Adkins
Medical Oncology.2020;[Epub] CrossRef
Biological Determinants of Chemo-Radiotherapy Response in HPV-Negative Head and Neck Cancer: A Multicentric External Validation
Martijn van der Heijden, Paul B. M. Essers, Monique C. de Jong, Reinout H. de Roest, Sebastian Sanduleanu, Caroline V. M. Verhagen, Olga Hamming-Vrieze, Frank Hoebers, Philippe Lambin, Harry Bartelink, C. René Leemans, Marcel Verheij, Ruud H. Brakenhoff,
Frontiers in Oncology.2020;[Epub] CrossRef
Molecular subtypes of oropharyngeal cancer show distinct immune microenvironment related with immune checkpoint blockade response
Min Hwan Kim, Jae-Hwan Kim, Ji Min Lee, Jae Woo Choi, Dongmin Jung, Hojin Cho, Hyundeok Kang, Min Hee Hong, Su Jin Heo, Se Heon Kim, Eun Chang Choi, Da Hee Kim, Young Min Park, Sangwoo Kim, Sun Och Yoon, Yoon Woo Koh, Byoung Chul Cho, Hye Ryun Kim
British Journal of Cancer.2020; 122(11): 1649. CrossRef
Establishment and characterization of patient-derived xenografts as paraclinical models for head and neck cancer
Han Na Kang, Jae-Hwan Kim, A-Young Park, Jae Woo Choi, Sun Min Lim, Jinna Kim, Eun Joo Shin, Min Hee Hong, Kyoung-Ho Pyo, Mi Ran Yun, Dong Hwi Kim, Hanna Lee, Sun Och Yoon, Da Hee Kim, Young Min Park, Hyung Kwon Byeon, Inkyung Jung, Soonmyung Paik, Yoon W
BMC Cancer.2020;[Epub] CrossRef
Impact of genetic variants in clinical outcome of a cohort of patients with oropharyngeal squamous cell carcinoma
Ana Carolina de Carvalho, Sandra Perdomo, Wellington dos Santos, Gabriela Carvalho Fernandes, Lais Machado de Jesus, Raiany Santos Carvalho, Cristovam Scapulatempo-Neto, Gisele Caravina de Almeida, Bruna Pereira Sorroche, Lidia Maria Rebolho Batista Arant
Scientific Reports.2020;[Epub] CrossRef
Prognostic Value of CD200R1 mRNA Expression in Head and Neck Squamous Cell Carcinoma
Hyun Chang, Yun-Gyoo Lee, Yoon Ho Ko, Jang Ho Cho, Jong-Kwon Choi, Keon Uk Park, Eun Joo Kang, Keun-Wook Lee, Sun Min Lim, Jin-Soo Kim, Hyun Woo Lee, Min Kyoung Kim, In Gyu Hwang, Sangwoo Kim, Byung-Ho Nam, Hye Ryun Kim
Cancers.2020; 12(7): 1777. CrossRef
Mouse–human co-clinical trials demonstrate superior anti-tumour effects of buparlisib (BKM120) and cetuximab combination in squamous cell carcinoma of head and neck
Hye Ryun Kim, Han Na Kang, Mi Ran Yun, Kwon Young Ju, Jae Woo Choi, Dong Min Jung, Kyoung Ho Pyo, Min Hee Hong, Myoung-Ju Ahn, Jong-Mu Sun, Han Sang Kim, Jinna Kim, Jinseon Yoo, Kyu Ryung Kim, Yoon Woo Koh, Se Heon Kim, Eun Chang Choi, Sun Ock Yoon, Hyo S
British Journal of Cancer.2020; 123(12): 1720. CrossRef
Mutationssignaturen beim Kopf- und Hals-Tumor
M. Plath, J. Hess, K. Zaoui
HNO.2020; 68(12): 922. CrossRef
BAMixChecker: an automated checkup tool for matched sample pairs in NGS cohort
Hein Chun, Sangwoo Kim, Inanc Birol
Bioinformatics.2019; 35(22): 4806. CrossRef
Diagnostic Tumor Markers in Head and Neck Squamous Cell Carcinoma (HNSCC) in the Clinical Setting
Panagiota Economopoulou, Remco de Bree, Ioannis Kotsantis, Amanda Psyrri
Frontiers in Oncology.2019;[Epub] CrossRef
A Review of HPV-Related Head and Neck Cancer
Kazuhiro Kobayashi, Kenji Hisamatsu, Natsuko Suzui, Akira Hara, Hiroyuki Tomita, Tatsuhiko Miyazaki
Journal of Clinical Medicine.2018; 7(9): 241. CrossRef

15,739 View
651 Download
35 Web of Science
35 Crossref

Prognostic Factors for Risk Stratification of Patients with Recurrent or Metastatic Pancreatic Adenocarcinoma Who Were Treated with Gemcitabine-Based Chemotherapy: Inkeun Park, Seung Joon Choi, Young Saing Kim, Hee Kyung Ahn, Junshik Hong, Sun Jin Sym, Jinny Park, Eun Kyung Cho, Jae Hoon Lee, Yong Ju Shin, Dong Bok Shin; Cancer Res Treat. 2016;48(4):1264-1273. Published online March 23, 2016; DOI: https://doi.org/10.4143/crt.2015.250

Abstract PDF PubReader ePub

Purpose
The aim of this study was to verify prognostic factors including sarcopenia in patients with recurrent or metastatic pancreatic cancer receiving gemcitabine-based chemotherapy. Materials and Methods Medical records and computed tomography scan of consecutive patients treated with palliative gemcitabine-based chemotherapy from 2008 to 2014 were reviewed. The lumbar skeletal muscle index at third lumbar spine level was computed, and together with clinicolaboratory factors, univariate and multivariable analyses for overall survival (OS) were performed.
Results
A total of 88 patients were found. Median age was 65 years, and male patients were predominant (67.0%). Most patients had initially metastatic disease (72.7%), and gemcitabine monotherapy was administered in 29 patients (33.0%) while gemcitabine plus erlotinib was administered in 59 patients (67.0%). Seventy-six patients (86.3%) had sarcopenia. With a median follow-up period of 44.3 months (range, 0.6 to 44.3 months), median OS was 5.35 months (95% confidence interval [CI], 4.11 to 6.59). In univariate and multivariable analysis, high carcinoembryonic antigen level (hazard ratio [HR], 4.18; 95% CI, 1.95 to 8.97; p < 0.001), initially metastatic disease (HR, 3.37; 95% CI, 1.55 to 7.32; p=0.002), sarcopenia (HR, 2.97; 95% CI, 1.20 to 7.36; p=0.019), neutrophilia (HR, 2.94; 95% CI, 1.27 to 6.79; p=0.012), and high lactate dehydrogenase level (HR, 1.96; 95% CI, 1.07 to 3.58; p=0.029) were identified as independent prognostic factors for OS. Conclusion Five independent prognostic factors in patients with recurrent or metastatic pancreatic cancer who received gemcitabine-based chemotherapy were identified. These findings may be helpful in prediction of prognosis in clinical practice and can be used as a stratification factor for clinical trials.

Citations

Citations to this article as recorded by

Computed Tomography-Based Sarcopenia and Pancreatic Cancer Survival—A Comprehensive Meta-Analysis Exploring the Influence of Definition Criteria, Prevalence, and Treatment Intention
Antonio Jesús Láinez Ramos-Bossini, Antonio Gámez Martínez, David Luengo Gómez, Francisco Valverde-López, Antonio Jesús Morillo Gil, Encarnación González Flores, Ángela Salmerón Ruiz, Paula María Jiménez Gutiérrez, Consolación Melguizo, José Prados
Cancers.2025; 17(4): 607. CrossRef
Looking at or beyond the tumor - a systematic review and meta-analysis of quantitative imaging biomarkers predicting pancreatic cancer prognosis
Zihe Wang, Liang Zhu, Yitan Wang, Xianlin Han, Qiang Xu, Menghua Dai
Abdominal Radiology.2025;[Epub] CrossRef
Prognostic value of deep learning-derived body composition in advanced pancreatic cancer—a retrospective multicenter study
J. Keyl, A. Bucher, F. Jungmann, R. Hosch, A. Ziller, R. Armbruster, P. Malkomes, T.M. Reissig, S. Koitka, I. Tzianopoulos, P. Keyl, K. Kostbade, D. Albers, P. Markus, J. Treckmann, K. Nassenstein, J. Haubold, M. Makowski, M. Forsting, H.A. Baba, S. Kaspe
ESMO Open.2024; 9(1): 102219. CrossRef
Body composition measures as a determinant of Alpelisib related toxicity
Eliya Shachar, Ari Raphael, Uriel Katz, Rivka Kessner, Shlomit Strulov Shachar
Breast Cancer Research and Treatment.2024; 206(2): 369. CrossRef
The relationship between LDH and GLIM criteria for cancer cachexia: Systematic review and meta-analysis
Joshua J. Thompson, Josh McGovern, Campbell S.D. Roxburgh, Joanne Edwards, Ross D. Dolan, Donald C. McMillan
Critical Reviews in Oncology/Hematology.2024; 199: 104378. CrossRef
Prevalence of Sarcopenia Determined by Computed Tomography in Pancreatic Cancer: A Systematic Review and Meta-Analysis of Observational Studies
Antonio Jesús Láinez Ramos-Bossini, Antonio Gámez Martínez, David Luengo Gómez, Francisco Valverde-López, Consolación Melguizo, José Prados
Cancers.2024; 16(19): 3356. CrossRef
Sarkopenie als unabhängiger Prognosefaktor bei Pankreaskarzinom
Johanna Mandl, Sebastian Baumer, Bernadette Holtzem, Rainer Theurer, Niels Zorger, Oliver Pech
Zeitschrift für Gastroenterologie.2023; 61(10): 1365. CrossRef
Association between Body Composition and Peripheral Neurotoxicity in Cancer Patients from North China Taking Nab-Paclitaxel
Jiayuan Guo, Juan Zhao, Ming Gu, Jixiang Hou, Ting Xu, Ying Jiang, Caihong Jiang, Hui Li, Xiaorong Li, Guang Liu, Lanzhen Zhao, Gaowa Jin, Yongzhi Shi, Ting Liu, Zhenhao Li, Zewei Zhang, Quanfu Li
Nutrition and Cancer.2023; 75(3): 805. CrossRef
Sarcopenia is an Independent Prognostic Factor in Patients With Pancreatic Cancer – a Meta-analysis
Maximilian Thormann, Mattes Hinnerichs, Felix Barajas Ordonez, Sylvia Saalfeld, Aristoteles Perrakis, Roland Croner, Jazan Omari, Maciej Pech, Marina Zamsheva, Hans-Jonas Meyer, Andreas Wienke, Alexey Surov
Academic Radiology.2023; 30(8): 1552. CrossRef
Pre-Therapeutic Sarcopenia among Cancer Patients: An Up-to-Date Meta-Analysis of Prevalence and Predictive Value during Cancer Treatment
Anne-Laure Couderc, Evelyne Liuu, Pascaline Boudou-Rouquette, Johanne Poisson, Maxime Frelaut, Coline Montégut, Soraya Mebarki, Romain Geiss, Zoé ap Thomas, Aurélien Noret, Monica Pierro, Capucine Baldini, Elena Paillaud, Frédéric Pamoukdjian
Nutrients.2023; 15(5): 1193. CrossRef
Association of myosteatosis with treatment response and survival in patients with hepatocellular carcinoma undergoing chemoembolization: a retrospective cohort study
Kittipitch Bannangkoon, Keerati Hongsakul, Teeravut Tubtawee, Natee Ina, Ply Chichareon
Scientific Reports.2023;[Epub] CrossRef
Prognostic value of pretreatment skeletal muscle index in pancreatic carcinoma patients: A meta-analysis
Li Yang, Xianghui Liao, Zhong Xie, Haiwen Li
Medicine.2023; 102(19): e33663. CrossRef
Is Computed-Tomography-Based Body Composition a Reliable Predictor of Chemotherapy-Related Toxicity in Pancreatic Cancer Patients?
Marco Cefalì, Isabel Scala, Giuliana Pavone, Daniel Helbling, Saskia Hussung, Ralph Fritsch, Cäcilia Reiner, Soleen Stocker, Dieter Koeberle, Marc Kissling, Vito Chianca, Filippo Del Grande, Sara De Dosso, Stefania Rizzo
Cancers.2023; 15(17): 4398. CrossRef
Sarkopenie als unabhängiger Prognosefaktor bei Pankreaskarzinom
Johanna Mandl, Sebastian Baumer, Bernadette Holtzem, Rainer Theurer, Niels Zorger, Oliver Pech
TumorDiagnostik & Therapie.2023; 44(10): 696. CrossRef
Gastrointestinal Cancer Patient Nutritional Management: From Specific Needs to Novel Epigenetic Dietary Approaches
Chiara Cencioni, Ilaria Trestini, Geny Piro, Emilio Bria, Giampaolo Tortora, Carmine Carbone, Francesco Spallotta
Nutrients.2022; 14(8): 1542. CrossRef
Sarcopenia
Hiroyuki Asama, Makoto Ueno, Satoshi Kobayashi, Taito Fukushima, Kuniyuki Kawano, Yusuke Sano, Satoshi Tanaka, Shuhei Nagashima, Manabu Morimoto, Hiromasa Ohira, Shin Maeda
Pancreas.2022; 51(2): 148. CrossRef
Prognostic significance of sarcopenia as determined by bioelectrical impedance analysis in patients with advanced pancreatic cancer receiving gemcitabine plus nab‑paclitaxel: A retrospective study
Yuichiro Tozuka, Makoto Ueno, Satoshi Kobayashi, Manabu Morimoto, Taito Fukushima, Yusuke Sano, Kuniyuki Kawano, Akane Hanaoka, Shun Tezuka, Hiroyuki Asama, Satoshi Moriya, Soichiro Morinaga, Shinichi Ohkawa, Shin Maeda
Oncology Letters.2022;[Epub] CrossRef
Body composition as a predictor of chemotherapy-related toxicity in pancreatic cancer patients: A systematic review
Stefania Rizzo, Isabel Scala, Angela Rodriguez Robayo, Marco Cefalì, Sara De Dosso, Stefano Cappio, Genti Xhepa, Filippo Del Grande
Frontiers in Oncology.2022;[Epub] CrossRef
Dynamic changes in the body composition during chemotherapy for gastrointestinal tumors in the context of active nutrition intervention
Ting Xu, Zhenhao Li, Hui Li, Jixiang Hou, Jingjing Li, Gaowa Jin, Shaohua Li, Quanfu Li
Frontiers in Oncology.2022;[Epub] CrossRef
Prognostic value of skeletal muscle mass during tyrosine kinase inhibitor (TKI) therapy in cancer patients: a systematic review and meta-analysis
Emanuele Rinninella, Marco Cintoni, Pauline Raoul, Francesca Romana Ponziani, Maurizio Pompili, Carmelo Pozzo, Antonia Strippoli, Emilio Bria, Giampaolo Tortora, Antonio Gasbarrini, Maria Cristina Mele
Internal and Emergency Medicine.2021; 16(5): 1341. CrossRef
Clinical significance of skeletal muscle density and sarcopenia in patients with pancreatic cancer undergoing first-line chemotherapy: a retrospective observational study
In-Ho Kim, Moon Hyung Choi, In Seok Lee, Tae Ho Hong, Myung Ah. Lee
BMC Cancer.2021;[Epub] CrossRef
The impact of body composition on short-term outcomes of neoadjuvant chemotherapy with gemcitabine plus S-1 in patients with resectable pancreatic cancer
Tsuyoshi Takeda, Takashi Sasaki, Takafumi Mie, Takaaki Furukawa, Yuto Yamada, Akiyoshi Kasuga, Masato Matsuyama, Masato Ozaka, Naoki Sasahira
Japanese Journal of Clinical Oncology.2021; 51(4): 604. CrossRef
Prognostic significance of skeletal muscle decrease in unresectable pancreatic cancer: Survival analysis using the Weibull exponential distribution model
Hiroki Sato, Takuma Goto, Akihiro Hayashi, Hidemasa Kawabata, Tetsuhiro Okada, Shuhei Takauji, Junpei Sasajima, Katsuro Enomoto, Mikihiro Fujiya, Kyohei Oyama, Yusuke Ono, Ayumu Sugitani, Yusuke Mizukami, Toshikatsu Okumura
Pancreatology.2021; 21(5): 892. CrossRef
Current situation, consensus and controversy of perioperative nutrition management in pancreatic surgery: A narrative review
Jingyong Xu, Junmin Wei
Journal of Pancreatology.2021; 4(1): 37. CrossRef
Maintenance of skeletal muscle mass during FOLFIRINOX is a favorable prognostic factor in pancreatic cancer patients
Dong Woo Shin, Minseok Albert Kim, Jong-chan Lee, Jaihwan Kim, Jin-Hyeok Hwang
BMC Research Notes.2021;[Epub] CrossRef
Depletion of Psoas Muscle Mass after Systemic Chemotherapy Is Associated with Poor Prognosis in Patients with Unresectable Pancreatic Cancer
Naoto Iwai, Takashi Okuda, Kohei Oka, Junichi Sakagami, Taishi Harada, Tomoya Ohara, Chie Hattori, Masashi Taniguchi, Hiroaki Sakai, Tasuku Hara, Toshifumi Tsuji, Toshiyuki Komaki, Keizo Kagawa, Osamu Dohi, Hiroaki Yasuda, Yoshito Itoh
Cancers.2021; 13(15): 3860. CrossRef
Neoadjuvant treatment: A window of opportunity for nutritional prehabilitation in patients with pancreatic ductal adenocarcinoma
Ilaria Trestini, Marco Cintoni, Emanuele Rinninella, Futura Grassi, Salvatore Paiella, Roberto Salvia, Emilio Bria, Carmelo Pozzo, Sergio Alfieri, Antonio Gasbarrini, Giampaolo Tortora, Michele Milella, Maria Cristina Mele
World Journal of Gastrointestinal Surgery.2021; 13(9): 885. CrossRef
Circulating Immunological Biomarkers
Fleur van der Sijde, Dana A.M. Mustafa, Eveline E. Vietsch, Peter D. Katsikis, Casper H. J. van Eijck
Pancreas.2021; 50(7): 933. CrossRef
Influence of sarcopenia in major pancreatic surgery. A systematic review of the literature
Raquel Aranzazu Latorre Fragua, Alba Manuel Vázquez, Carmen Ramiro Pérez, Roberto de la Plaza Llamas, José Manuel Ramia Ángel
Gastroenterología y Hepatología.2020; 43(3): 142. CrossRef
Serum miR-338-3p and miR-199b-5p are associated with the absolute neutrophil count in patients with resectable pancreatic cancer
Fleur van der Sijde, Eveline E. Vietsch, Dana A.M. Mustafa, Yunlei Li, Casper H.J. van Eijck
Clinica Chimica Acta.2020; 505: 183. CrossRef
Influence of sarcopenia in major pancreatic surgery. A systematic review of the literature
Raquel Aranzazu Latorre Fragua, Alba Manuel Vázquez, Carmen Ramiro Pérez, Roberto de la Plaza Llamas, José Manuel Ramia Ángel
Gastroenterología y Hepatología (English Edition).2020; 43(3): 142. CrossRef
The impact of sarcopenia on patients undergoing treatment for pancreatic ductal adenocarcinoma
Julia R. Amundson, Jelani K. Williams, Andrew J. Benjamin, Hunter D.D. Witmer, Kevin K. Roggin
Journal of Pancreatology.2020; 3(2): 59. CrossRef
Impact of progressive resistance training on CT quantified muscle and adipose tissue compartments in pancreatic cancer patients
Raoul Wochner, Dorothea Clauss, Johanna Nattenmüller, Christine Tjaden, Thomas Bruckner, Hans-Ulrich Kauczor, Thilo Hackert, Joachim Wiskemann, Karen Steindorf, Leonardo A. Peyré-Tartaruga
PLOS ONE.2020; 15(11): e0242785. CrossRef
Prognostic factors in patients with metastatic or recurrent pancreatic cancer treated with first-line nab-paclitaxel plus gemcitabine: implication of inflammation-based scores
Inhwan Hwang, Jihoon Kang, Hei Nga Natalie Ip, Jae Ho Jeong, Kyu-pyo Kim, Heung-Moon Chang, Changhoon Yoo, Baek-Yeol Ryoo
Investigational New Drugs.2019; 37(3): 584. CrossRef
Sarcopenia is a reliable prognostic factor in patients with advanced pancreatic cancer receiving FOLFIRINOX chemotherapy
Yusuke Kurita, Noritoshi Kobayashi, Motohiko Tokuhisa, Ayumu Goto, Kensuke Kubota, Itaru Endo, Atsushi Nakajima, Yasushi Ichikawa
Pancreatology.2019; 19(1): 127. CrossRef
Significance of the inflammation-based prognostic score in recurrent pancreatic cancer
Kenji Nakagawa, Masayuki Sho, Takahiro Akahori, Minako Nagai, Kota Nakamura, Tadataka Takagi, Toshihiro Tanaka, Hideyuki Nishiofuku, Chiho Ohbayashi, Kimihiko Kichikawa, Naoya Ikeda
Pancreatology.2019; 19(5): 722. CrossRef
Body composition assessment and sarcopenia in patients with pancreatic cancer: a systematic review and meta-analysis
James Bundred, Sivesh K. Kamarajah, Keith J. Roberts
HPB.2019; 21(12): 1603. CrossRef
Prognostic Significance of Sarcopenia in Patients with Unresectable Advanced Esophageal Cancer
Sachiyo Onishi, Masahiro Tajika, Tsutomu Tanaka, Yutaka Hirayama, Kazuo Hara, Nobumasa Mizuno, Takamichi Kuwahara, Nozomi Okuno, Yoshitaka Inaba, Takeshi Kodaira, Tetsuya Abe, Kei Muro, Masahito Shimizu, Yasumasa Niwa
Journal of Clinical Medicine.2019; 8(10): 1647. CrossRef
An update on treatment options for pancreatic adenocarcinoma
Aurélien Lambert, Lilian Schwarz, Ivan Borbath, Aline Henry, Jean-Luc Van Laethem, David Malka, Michel Ducreux, Thierry Conroy
Therapeutic Advances in Medical Oncology.2019;[Epub] CrossRef
Sarcopenia Predicts Prognosis in Patients with Newly Diagnosed Hepatocellular Carcinoma, Independent of Tumor Stage and Liver Function
Yeonjung Ha, Daejung Kim, Seungbong Han, Young Eun Chon, Yun Bin Lee, Mi Na Kim, Joo Ho Lee, Hana Park, Kyu Sung Rim, Seong Gyu Hwang
Cancer Research and Treatment.2018; 50(3): 843. CrossRef
The Obesity Paradox in Cancer: How Important Is Muscle?
Elizabeth M. Cespedes Feliciano, Candyce H. Kroenke, Bette J. Caan
Annual Review of Nutrition.2018; 38(1): 357. CrossRef
Dietary fat stimulates pancreatic cancer growth and promotes fibrosis of the tumor microenvironment through the cholecystokinin receptor
Sandeep Nadella, Julian Burks, Abdulhameed Al-Sabban, Gloria Inyang, Juan Wang, Robin D. Tucker, Marie E. Zamanis, William Bukowski, Narayan Shivapurkar, Jill P. Smith
American Journal of Physiology-Gastrointestinal and Liver Physiology.2018; 315(5): G699. CrossRef
Prognostic value of pretreatment serum lactate dehydrogenase level in pancreatic cancer patients
Jianxin Gan, Wenhu Wang, Zengxi Yang, Jiebin Pan, Liang Zheng, Lanning Yin
Medicine.2018; 97(46): e13151. CrossRef

12,151 View
227 Download
43 Web of Science
43 Crossref

A Retrospective Analysis for Patients with HER2-Positive Gastric Cancer Who Were Treated with Trastuzumab-Based Chemotherapy: In the Perspectives of Ethnicity and Histology: Jun Ho Yi, Jung Hun Kang, In Gyu Hwang, Hee Kyung Ahn, Hyun Jin Baek, Soon Il Lee, Do Hyoung Lim, Young-Woong Won, Jun Ho Ji, Hyo Song Kim, Sun Young Rha, Sung Yong Oh, Kyung Eun Lee, Taekyu Lim, Chi Hoon Maeng, Moon Jin Kim, Seung Tae Kim, Jeeyun Lee, Joon Oh Park, Young Suk Park, Ho Yeong Lim, Won Ki Kang, Se Hoon Park; Cancer Res Treat. 2016;48(2):553-560. Published online August 10, 2015; DOI: https://doi.org/10.4143/crt.2015.155

Abstract PDF PubReader ePub

Purpose
While the Trastuzumab for Gastric Cancer (ToGA) trial demonstrated the efficacy and safety of trastuzumab-based chemotherapy in HER2-positive metastatic gastric cancer, the overall survival (OS) benefit was not found in Asian and diffuse-type cancer patients. The aim of the study is to investigate predictive markers for trastuzumab-based chemotherapy.
Materials and Methods
Data of patients with HER2-positive gastric cancer treated with trastuzumab-based chemotherapy were analyzed retrospectively.
Results
A total of 168 Asian patients were included. The median age was 60 years (range, 27 to 85 years) and the male:female ratio was 118 (70.2%):50 (29.8%). Fourteen (8.3%), 63 (37.5%), 75 (44.6%), and 11 (6.5%) patients had well, moderately, poorly-differentiated tubular adenocarcinoma and signet ring cell carcinoma, respectively. With 14 complete responses and 73 partial responses, the response rate was 50.6%. The median progression-free survival (PFS) was 10.2 months (95% confidence interval [CI], 8.7 to 11.7), and the median OS was 18.5 months (95% CI, 16.4 to 50.6). Next, we investigated the effect of poorly-differentiated histology (PDH, poorly-differentiated tubular adenocarcinoma+signet ring cell carcinoma) on clinical outcomes. The median PFS (8.9 months vs. 11.5 months, p=0.16) was slightly inferior in PDH patients, and the median OS was significantly shorter in PDH patients (14.6 months vs. 19.0 months, p=0.025).
Conclusion
While subset analysis of the ToGA trial demonstrated that trastuzumab-based chemotherapy may not be beneficial for Asians and patients with PDH, our data may suggest that even in Asian patients and patients with PDH, trastuzumab-based chemotherapy could be associated with improved clinical outcomes in patients with HER2-positive gastric cancer.

Citations

Citations to this article as recorded by

Timing to Surgery and Lymph Node Upstaging in Gastric Cancer: An NCDB Analysis
Maria Cristina Riascos, Jacques A. Greenberg, Federico Palacardo, Rodrigo Edelmuth, V. Colby Lewis, Anjile An, Haythem Najah, Hala Al Asadi, Parima Safe, Brendan M. Finnerty, Paul J. Christos, Thomas J. Fahey, Rasa Zarnegar
Annals of Surgical Oncology.2024; 31(3): 1714. CrossRef
Deviating HER2 test results in gastric cancer: analysis from the prospective multicenter VARIANZ study
Katharina Kolbe, Ivonne Haffner, Katrin Schierle, Dieter Maier, Birgitta Geier, Birgit Luber, Hendrik Bläker, Christian Wittekind, Florian Lordick
Journal of Cancer Research and Clinical Oncology.2023; 149(3): 1319. CrossRef
Trastuzumab Combined With Ramucirumab and Paclitaxel in Patients With Previously Treated Human Epidermal Growth Factor Receptor 2–Positive Advanced Gastric or Gastroesophageal Junction Cancer
Chang Gon Kim, Minkyu Jung, Hyo Song Kim, Choong-kun Lee, Hei-Cheul Jeung, Dong-Hoe Koo, Woo Kyun Bae, Dae Young Zang, Bum Jun Kim, Hyunki Kim, Un-Jung Yun, Jingmin Che, Sejung Park, Tae Soo Kim, Woo Sun Kwon, Juin Park, Sang Woo Cho, Chung Mo Nam, Hyun C
Journal of Clinical Oncology.2023; 41(27): 4394. CrossRef
Novel HER2-targeted therapy to overcome trastuzumab resistance in HER2-amplified gastric cancer
Juin Park, Sun Kyoung Kang, Woo Sun Kwon, Inhye Jeong, Tae Soo Kim, Seo Young Yu, Sang Woo Cho, Hyun Cheol Chung, Sun Young Rha
Scientific Reports.2023;[Epub] CrossRef
Do proton pump inhibitors affect the effectiveness of chemotherapy in colorectal cancer patients? A systematic review with meta-analysis
Wan-Ying Lin, Shih-Syuan Wang, Yi-No Kang, Andrea S. Porpiglia, Yu Chang, Chin-Hsuan Huang, Ronak Bhimani, Eahab Abdul-Lattif, Muneeba Azmat, Tsu-Hsien Wang, Yu-Shiuan Lin, Yu-Cheng Chang, Kuan-Yu Chi
Frontiers in Pharmacology.2022;[Epub] CrossRef
Effectiveness of Trastuzumab in Routine Clinical Practice: A Population-based Study of Patients with HER-2-positive Oesophageal, Gastroesophageal and Gastric Cancer
S.J. Merchant, W. Kong, B. Gyawali, T. Hanna, W. Chung, S. Nanji, S.V. Patel, C.M. Booth
Clinical Oncology.2021; 33(3): 202. CrossRef
Trastuzumab-based palliative chemotherapy for HER2-positive gastric cancer: a single-center real-world data
Tae-Hwan Kim, Hun Do Cho, Yong Won Choi, Hyun Woo Lee, Seok Yun Kang, Geum Sook Jeong, Jin-Hyuk Choi, Mi Sun Ahn, Seung-Soo Sheen
BMC Cancer.2021;[Epub] CrossRef
HER2 Expression, Test Deviations, and Their Impact on Survival in Metastatic Gastric Cancer: Results From the Prospective Multicenter VARIANZ Study
Ivonne Haffner, Katrin Schierle, Elba Raimúndez, Birgitta Geier, Dieter Maier, Jan Hasenauer, Birgit Luber, Axel Walch, Katharina Kolbe, Jorge Riera Knorrenschild, Albrecht Kretzschmar, Beate Rau, Ludwig Fischer von Weikersthal, Miriam Ahlborn, Gabriele S
Journal of Clinical Oncology.2021; 39(13): 1468. CrossRef
Current therapeutic options for gastric adenocarcinoma
C.R. Akshatha, Smitha Bhat, R. Sindhu, Dharini Shashank, Sarana Rose Sommano, Wanaporn Tapingkae, Ratchadawan Cheewangkoon, Shashanka K. Prasad
Saudi Journal of Biological Sciences.2021; 28(9): 5371. CrossRef
Efficacy of Trastuzumab and Potential Risk Factors on Survival in Patients with HER2-Positive Metastatic Gastric Cancer
Atakan Topcu, Muhammed Mustafa Atci, Saban Secmeler, Mehmet Besiroglu, Murat Ayhan, Metin Ozkan, Oktay Bozkurt, Zuhat Urakci, Seval Ay, Caglayan Geredeli, Ayse Irem Yasin, Haci Mehmet Turk
Future Oncology.2021; 17(31): 4157. CrossRef
Reliability of Conclusions from Early Analyses of Real-World Data for Newly Approved Drugs in Advanced Gastric Cancer in the United States

Lisa M Hess, Michael Grabner, Liya Wang, Astra M Liepa, Xiaohong Ivy Li, Zhanglin Lin Cui, Lee Bowman, William R Schelman
Pragmatic and Observational Research.2020; Volume 11: 27. CrossRef
Targeting HER2-positive gastric cancer with a novel 18F-labeled ZHER2:342 probe
Yunyun Pan, Zhengyang Yang, Yuping Xu, Zhicheng Bai, Donghui Pan, Runlin Yang, Lizhen Wang, Wenxian Guan, Min Yang
RSC Advances.2019; 9(19): 10990. CrossRef
Clinical significance of overexpression of NRG1 and its receptors, HER3 and HER4, in gastric cancer patients
Sumi Yun, Jiwon Koh, Soo Kyung Nam, Jung Ok Park, Sung Mi Lee, Kyoungyul Lee, Kyu Sang Lee, Sang-Hoon Ahn, Do Joong Park, Hyung-Ho Kim, Gheeyoung Choe, Woo Ho Kim, Hye Seung Lee
Gastric Cancer.2018; 21(2): 225. CrossRef
Correlation of trastuzumab-based treatment with clinical characteristics and prognosis in HER2-positive gastric and gastroesophageal junction cancer: A retrospective single center analysis
A. Ilhan-Mutlu, H. Taghizadeh, A. Beer, W. Dolak, A. Ba-Ssalamah, S. F. Schoppmann, M. Hejna, P. Birner, M. Preusser
Cancer Biology & Therapy.2018; 19(3): 169. CrossRef
Docetaxel, oxaliplatin, 5FU, and trastuzumab as first-line therapy in patients with human epidermal receptor 2-positive advanced gastric or gastroesophageal junction cancer
Giandomenico Roviello, Roberto Petrioli, Valerio Nardone, Pietro Rosellini, Andrea Giovanni Multari, Raffaele Conca, Michele Aieta
Medicine.2018; 97(20): e10745. CrossRef

14,752 View
168 Download
18 Web of Science
15 Crossref

Randomized Phase II Study of Pemetrexed Versus Gefitinib in Previously Treated Patients with Advanced Non-small Cell Lung Cancer: Young Saing Kim, Eun Kyung Cho, Hyun Sun Woo, Junshik Hong, Hee Kyung Ahn, Inkeun Park, Sun Jin Sym, Sun Young Kyung, Shin Myung Kang, Jeong-Woong Park, Sung Hwan Jeong, Jinny Park, Jae Hoon Lee, Dong Bok Shin; Cancer Res Treat. 2016;48(1):80-87. Published online March 2, 2015; DOI: https://doi.org/10.4143/crt.2014.307

Abstract PDF PubReader ePub

Purpose
This study aimed to evaluate the efficacy and safety of pemetrexed versus gefitinib in patients with advanced non-small cell lung cancer (NSCLC) previously treated with chemotherapy. Materials and Methods Patients with advanced (stage IIIB or IV) or recurrent NSCLC were randomly assigned to receive either 500 mg/m² of pemetrexed intravenously every 3 weeks or gefitinib 250 mg/day orally. The primary end point was progression-free survival (PFS) at 6 months.
Results
A total of 95 patients were enrolled (47 for pemetrexed and 48 for gefitinib). Most patients were male (72%) and current/ex-smokers (69%), and 80% had non-squamous cell carcinoma. The epidermal growth factor receptor (EGFR) mutation status was determined in 38 patients (40%); one patient per each arm was positive for EGFRmutation. The 6-month PFS rates were 22% and 15% for pemetrexed and gefitinib, respectively (p=0.35). Both arms showed an identical median PFS of 2.0 months and a median overall survival (OS) of 8.5 months. In EGFR wild-type patients, higher response rate (RR) and longer PFS as well as OS were achieved via pemetrexed compared with gefitinib, although there were no significant differences (RR: 39% vs. 9%, p=0.07; median PFS: 6.6 months vs. 3.1 months, p=0.45; median OS: 29.6 months vs. 12.9 months, p=0.62). Toxicities were mild in both treatment arms. Frequently reported toxicities were anemia and fatigue for pemetrexed, and skin rash and anorexia for gefitinib. Conclusion Both pemetrexed and gefitinib had similar efficacy with good tolerability as second-line treatment in unselected patients with advanced NSCLC. However, pemetrexed is considered more effective than gefitinib for EGFR wild-type patients.

Citations

Citations to this article as recorded by

Adverse event profiles of EGFR-TKI: network meta-analysis and disproportionality analysis of the FAERS database
Jing Shi, Xinya Liu, Mengjiao Gao, Jian Yu, Ting Chai, Yun Jiang, Jiawei Li, Yuanming Zhang, Li Wu
Frontiers in Pharmacology.2025;[Epub] CrossRef
A network meta-analysis of immunotherapy-based treatments for advanced nonsquamous non-small cell lung cancer
Himani Aggarwal, Kerigo Ndirangu, Katherine B Winfree, Catherine Elizabeth Muehlenbein, Emily Zhu, Vanita Tongbram, Howard Thom
Journal of Comparative Effectiveness Research.2023;[Epub] CrossRef
Toxicity profile of epidermal growth factor receptor tyrosine kinase inhibitors for patients with lung cancer: A systematic review and network meta-analysis
Yi Zhao, Bo Cheng, Zisheng Chen, Jianfu Li, Hengrui Liang, Ying Chen, Feng Zhu, Caichen Li, Ke Xu, Shan Xiong, Weixiang Lu, Zhuxing Chen, Ran Zhong, Shen Zhao, Zhanhong Xie, Jun Liu, Wenhua Liang, Jianxing He
Critical Reviews in Oncology/Hematology.2021; 160: 103305. CrossRef
Efficacy and Safety of Pemetrexed and Gefitinib in the Treatment of Non-Small-Cell Lung Cancer: A Meta-Analysis
Zhihao Zhang, Xiyong Wang, Huaiqing Xiao, Dongqiang Wu, Dongliang Zhang, Qun Yu, Linna Yuan, Tao Huang
Computational and Mathematical Methods in Medicine.2021; 2021: 1. CrossRef
A meta-analysis of the safety and effectiveness of pemetrexed compared with gefitinib for pre-treated advanced or metastatic NSCLC
Xiaoxin Lu, Shengshu Li, Weizong Chen, Dongyang Zheng, Yuzhu Li, Fang Li
Medicine.2020; 99(29): e21170. CrossRef
Pemetrexed versus Gefitinib as Second-line Treatment for Advanced Non-small Cell Lung Cancer: A Meta-analysis Based on Randomized Controlled Trials
Huiyu Wang, Zunjing Zhang, Feng Liu, Miaoying Zhou, Handi Lv
Pteridines.2019; 30(1): 171. CrossRef
Gefitinib for advanced non-small cell lung cancer
Esther HA Sim, Ian A Yang, Richard Wood-Baker, Rayleen V Bowman, Kwun M Fong
Cochrane Database of Systematic Reviews.2018;[Epub] CrossRef
Pneumonitis in advanced non-small-cell lung cancer patients treated with EGFR tyrosine kinase inhibitor: Meta-analysis of 153 cohorts with 15,713 patients
Chong Hyun Suh, Hye Sun Park, Kyung Won Kim, Junhee Pyo, Hiroto Hatabu, Mizuki Nishino
Lung Cancer.2018; 123: 60. CrossRef
Second-Line Treatment of NSCLC—The Pan-ErbB Inhibitor Afatinib in Times of Shifting Paradigms
Jens Köhler
Frontiers in Medicine.2017;[Epub] CrossRef

13,560 View
127 Download
16 Web of Science
9 Crossref

Oxaliplatin-Induced Immune-Mediated Thrombocytopenia: A Case Report: Hyun Sun Woo, Kyoung Hwa Lee, Phill Hoon Yoon, Su Ji Kim, Inkeun Park, Young Saing Kim, Hee Kyung Ahn, Junshik Hong, Dong Bok Shin, Sun Jin Sym; Cancer Res Treat. 2015;47(4):949-953. Published online October 28, 2014; DOI: https://doi.org/10.4143/crt.2014.052

Abstract PDF PubReader ePub

Oxaliplatin is a third-generation platinum derivative used for metastatic or advanced colorectal cancer treatment. Although myelosuppression is the most common cause of oxaliplatin-induced thrombocytopenia, rare cases of oxaliplatin-induced immunemediated thrombocytopenia are reported. We report a case of a 57-year-old woman with colon cancer who developed gum bleeding and petechiae after oxaliplatin infusion. Laboratory tests revealed grade 4 thrombocytopenia and grade 4 neutropenia. She recovered from the thrombocytopenia and accompanying neutropenia within 4 days with no recurrence following discontinuation of oxaliplatin. Physicians need to be aware of the risk of severe acute thrombocytopenia following oxaliplatin administration.

Citations

Citations to this article as recorded by

Risk Factors of Chemotherapy-Induced Thrombocytopenia After Oxaliplatin-Containing Chemotherapy for Gastrointestinal Malignancies
Ju Li, Wanqing Wang, Kaipeng Jiang, Jiuwei Cui, Chang Wang, Tingting Liang, Yizhuo Wang, Shuhan Liu, Wenshuo Zhou
Journal of Gastrointestinal Cancer.2024; 55(3): 1144. CrossRef
Oxaliplatin Antibody-Related Thrombocytopenia: A Case Report
Khin Pyai, David I LeRoy, Joseph Attallah, Hosam Hakim, Zyad Kafri
Cureus.2024;[Epub] CrossRef
The Many Faces of Immune Thrombocytopenia: Mechanisms, Therapies, and Clinical Challenges in Oncological Patients
Marek Kos, Piotr Tomaka, Paulina Mertowska, Sebastian Mertowski, Julia Wojnicka, Anna Błażewicz, Ewelina Grywalska, Krzysztof Bojarski
Journal of Clinical Medicine.2024; 13(22): 6738. CrossRef
Severe ileum bleeding following adjuvant capecitabine chemotherapy for locally advanced colon cancer: a case report and review of the literature
You Zou, Shuang Liu, Jianhong Wu, Zhen Sun
World Journal of Surgical Oncology.2021;[Epub] CrossRef
A case of idiosyncratic liver injury after oxaliplatin‐induced thrombocytopenia
Shinji Honda, Masayuki Tsujimoto, Tetsuya Minegaki, Tomohiko Mori, Junji Muraoka, Kohshi Nishiguchi
Journal of Clinical Pharmacy and Therapeutics.2020; 45(2): 373. CrossRef
Ototoxicity and Platinum Uptake Following Cyclic Administration of Platinum-Based Chemotherapeutic Agents
Benjamin K. Gersten, Tracy S. Fitzgerald, Katharine A. Fernandez, Lisa L. Cunningham
Journal of the Association for Research in Otolaryngology.2020; 21(4): 303. CrossRef
Oxaliplatin-Induced Thrombocytopenia: A Case Report and Review of Pathophysiology of Various Speculative Mechanisms
Haider Ghazanfar, Iqra Nawaz, Nisha Ali
Cureus.2020;[Epub] CrossRef
Oxaliplatin Treatment Alters Systemic Immune Responses
Vanesa Stojanovska, Monica Prakash, Rachel McQuade, Sarah Fraser, Vasso Apostolopoulos, Samy Sakkal, Kulmira Nurgali
BioMed Research International.2019; 2019: 1. CrossRef
Oxaliplatin Immune-Induced Syndrome Occurs With Cumulative Administration and Rechallenge: Single Institution Series and Systematic Review Study
Katia Bencardino, Gianluca Mauri, Alessio Amatu, Federica Tosi, Erica Bonazzina, Laura Palmeri, Marialuisa Querques, Federica Ravera, Alberto Menegotto, Elisa Boiani, Andrea Sartore-Bianchi, Salvatore Siena
Clinical Colorectal Cancer.2016; 15(3): 213. CrossRef

12,992 View
117 Download
10 Web of Science
9 Crossref

Nomogram to Predict Treatment Outcome of Fluoropyrimidine/Platinum-Based Chemotherapy in Metastatic Esophageal Squamous Cell Carcinoma: Hyun Ae Jung, Antoine Adenis, Jeeyun Lee, Se Hoon Park, Chi Hoon Maeng, Silvia Park, Hee Kyung Ahn, Young Mog Shim, Nicolas Penel, Young-Hyuck Im; Cancer Res Treat. 2013;45(4):285-294. Published online December 31, 2013; DOI: https://doi.org/10.4143/crt.2013.45.4.285

Abstract PDF PubReader ePub

PURPOSE
The degree of benefit from palliative chemotherapy differs widely among patients with metastatic esophageal squamous cell carcinoma (MESCC). The purpose of this study was to develop and validate a prognostic nomogram to predict survival and aid physicians and patients in the decision-making process regarding treatment options.
MATERIALS AND METHODS
Clinicopathologic variables and treatment outcomes of 239 patients who were diagnosed with MESCC and received either fluorouracil/cisplatin (FP) or capecitabine/cisplatin (XP) as first-line chemotherapy were reviewed. A nomogram was developed as a prognostic scoring system incorporating significant clinical and laboratory variables based on a multivariate Cox proportional hazards regression model. An independent series of 61 MESCC patients treated with FP served as an independent data set for nomogram validation.
RESULTS
No difference in response rate was observed between the FP group (44.8%) and the XP group (54.2%). Similarly, no significant differences in median progression-free survival and median overall survival were observed between regimen groups. Multivariate analysis showed that poor performance status (Eastern Cooperative Oncology Group [ECOG] status> or =2), weight loss (10% of the weight loss for 3 months), low albumin level (< or =3.5 g/dL), and absence of previous esophagectomy at the time of chemotherapy were significantly associated with low OS in both groups (p<0.05). Based on these findings, patients were classified into favorable (score, 0 to 90), intermediate (91-134), and poor (>135) prognostic groups. The median survival for those with a favorable ECOG was 13.8 months (95% confidence interval [CI], 10.8 to 18.6 months), for intermediate 11.2 months (95% CI, 8.7 to 11.9 months), and for poor, 7.0 months (95% CI, 3.6 to 10.0 months). External validation of the nomogram in a different patient cohort yielded significantly similar findings.
CONCLUSION
The nomogram described here predicts survival in MESCC patients and could serve as a guide for the use of FP/XP chemotherapy in MESCC patients.

Citations

Citations to this article as recorded by

A population-based investigation: How to identify high-risk T1-2N0 esophageal cancer patients?
Peng Luo, Jie Wu, Xiankai Chen, Yafan Yang, Ruixiang Zhang, Xiuzhu Qi, Yin Li
Frontiers in Surgery.2023;[Epub] CrossRef
Low-Dose Versus High-Dose Radiation Therapy for the Palliation of Dysphagia From Esophageal Cancer: A Multicenter Retrospective Cohort Study
Bram D. Vermeulen, Paul M. Jeene, Jasmijn Sijben, Robin Krol, Heidi Rütten, Johannes A. Bogers, Pètra M. Braam, Peter D. Siersema
Practical Radiation Oncology.2020; 10(4): e255. CrossRef
Chemo-immune synergetic therapy of esophageal carcinoma: trastuzumab modified, cisplatin and fluorouracil co-delivered lipid–polymer hybrid nanoparticles
Qingxia Fu, Jiancheng Wang, Hong Liu
Drug Delivery.2020; 27(1): 1535. CrossRef
A Novel Nomogram and Risk Classification System Predicting the Cancer-Specific Survival of Patients with Initially Diagnosed Metastatic Esophageal Cancer: A SEER-Based Study
Xin Tang, Xiaojuan Zhou, Yanying Li, Xue Tian, Yongsheng Wang, Meijuan Huang, Li Ren, Lin Zhou, Zhenyu Ding, Jiang Zhu, Yong Xu, Feng Peng, Jin Wang, You Lu, Youling Gong
Annals of Surgical Oncology.2019; 26(2): 321. CrossRef
SOURCE: A Registry-Based Prediction Model for Overall Survival in Patients with Metastatic Oesophageal or Gastric Cancer
Héctor van den Boorn, Ameen Abu-Hanna, Emil ter Veer, Jessy van Kleef, Florian Lordick, Michael Stahl, Jaffer Ajani, Rosine Guimbaud, Se Park, Susan Dutton, Yung-Jue Bang, Narikazu Boku, Nadia Mohammad, Mirjam Sprangers, Rob Verhoeven, Aeilko Zwinderman,
Cancers.2019; 11(2): 187. CrossRef
Evaluation of Prognostic Factors for Esophageal Squamous Cell Carcinoma Treated with Neoadjuvant Chemoradiotherapy Followed by Surgery
Yoichi Hamai, Jun Hihara, Manabu Emi, Takaoki Furukawa, Yuji Murakami, Ikuno Nishibuchi, Yuta Ibuki, Ichiko Yamakita, Tomoaki Kurokawa, Yasushi Nagata, Morihito Okada
World Journal of Surgery.2018; 42(5): 1496. CrossRef
Prediction models for patients with esophageal or gastric cancer: A systematic review and meta-analysis
H. G. van den Boorn, E. G. Engelhardt, J. van Kleef, M. A. G. Sprangers, M. G. H. van Oijen, A. Abu-Hanna, A. H. Zwinderman, V. M. H. Coupé, H. W. M. van Laarhoven, Masaru Katoh
PLOS ONE.2018; 13(2): e0192310. CrossRef
Survival prediction tools for esophageal and gastroesophageal junction cancer: A systematic review
Vaibhav Gupta, Natalie Coburn, Biniam Kidane, Kenneth R. Hess, Carolyn Compton, Jolie Ringash, Gail Darling, Alyson L. Mahar
The Journal of Thoracic and Cardiovascular Surgery.2018; 156(2): 847. CrossRef
First-Line Chemotherapy for Metastatic Esophageal Squamous Cell Carcinoma: Clinico-Biological Predictors of Disease Control
Nuria Kotecki, Sandrine Hiret, Pierre-Luc Etienne, Nicolas Penel, Emmanuelle Tresch, Eric François, Marie Pierre Galais, Meher Ben Abdelghani, Pierre Michel, Laetitia Dahan, François Ghiringelli, Laurent Bedenne, Emmanuelle Samalin, Guillaume Piessen, Jaf
Oncology.2016; 90(2): 88. CrossRef
Development and Validation of a Prognostic Nomogram for Progression-Free Survival in Patients with Advanced Renal Cell Carcinoma Treated with Pazopanib
Michael W. Kattan, Cora N. Sternberg, Faisal Mehmud, Kamal Bhatt, Lauren McCann, Robert J. Motzer
Oncology.2015; 89(4): 235. CrossRef
Nomogram to Predict Treatment Outcome of Fluoropyrimidine/Platinum-Based Chemotherapy in Metastatic Esophageal Squamous Cell Carcinoma
Hyun Ae Jung, Antoine Adenis, Jeeyun Lee, Se Hoon Park, Chi Hoon Maeng, Silvia Park, Hee Kyung Ahn, Young Mog Shim, Nicolas Penel, Young-Hyuck Im
Cancer Research and Treatment.2013; 45(4): 285. CrossRef

12,016 View
88 Download
11 Crossref

A Case Report of Paraneoplastic Pemphigus Associated with Esophageal Squamous Cell Carcinoma: Jin Hyun Cho, Nam Jun Kim, Sung Min Ko, Chunghun Kim, Hee Kyung Ahn, Jina Yun, Yeon Hee Park; Cancer Res Treat. 2013;45(1):70-73. Published online March 31, 2013; DOI: https://doi.org/10.4143/crt.2013.45.1.70

Abstract PDF PubReader ePub

Paraneoplastic pemphigus is an autoimmune blistering and erosive mucocutaneous syndrome associated with underlying neoplasm. It is primarily associated with lymphoproliferative disorders, and uncommonly with malignancies of epithelial origin. We report on a case of a 68-year-old male who presented with whole body bullous and erosive skin lesions. Findings on upper gastrointestinal endoscopy and skin biopsy revealed esophageal squamous cell carcinoma and paraneoplastic pemphigus. Palliative chemotherapy and systemic glucocorticoid were started, however, the patient died of overwhelming sepsis on the ninth day of chemotherapy. This case demonstrates that paraneoplastic pemphigus can occur in esophageal squamous cell carcinoma and could be a cause of morbidity.

Citations

Citations to this article as recorded by

Paraneoplastic pemphigus: a rare case
Thota Pravallika, K. V. T. Gopal, P. V. Krishnam Raju, B. Rekha Rani
International Journal of Research in Dermatology.2025; 11(3): 280. CrossRef
Paraneoplastic pemphigus/paraneoplastic autoimmune multiorgan syndrome: Part I. Clinical overview and pathophysiology
Hannah J. Anderson, Simo Huang, Jason B. Lee
Journal of the American Academy of Dermatology.2024; 91(1): 1. CrossRef
T cell autoimmunity and immune regulation to desmoglein 3, a pemphigus autoantigen
Hayato Takahashi, Hisato Iriki, Yasuhiko Asahina
The Journal of Dermatology.2023; 50(2): 112. CrossRef
S2k guidelines on the management of paraneoplastic pemphigus/paraneoplastic autoimmune multiorgan syndrome initiated by the European Academy of Dermatology and Venereology (EADV)
Emiliano Antiga, Rikke Bech, Roberto Maglie, Giovanni Genovese, Luca Borradori, Barbara Bockle, Marzia Caproni, Frédéric Caux, Nisha Suyien Chandran, Alberto Corrà, Francesco D'Amore, Maryam Daneshpazhooh, Dipankar De, Dario Didona, Marian Dmochowski, Kos
Journal of the European Academy of Dermatology and Venereology.2023; 37(6): 1118. CrossRef
A Case of Severe Refractory Pemphigus Vulgaris in a Patient With Stable Esophageal Malignancy
Vanessa C Browne, Catherine Choi, Eugenio M Capitle, Reena Khianey
Cureus.2021;[Epub] CrossRef
Paraneoplastic pemphigus and cutaneous squamous cell carcinoma: uncommun 3 cases
Afaf Khouna
Journal of Dermatology & Cosmetology.2021; 5(1): 17. CrossRef
Pemphigus Vulgaris and Bullous Pemphigoid of the Upper Aerodigestive Tract: A Review Article and Novel Approaches to Management
Mohammed Hassan Hussain, Faiz Tanweer, Georgios Sakagiannis, Manish Mair, Sara Mahmood, Sithamparappillai Ashokkumar
ORL.2021; 83(6): 395. CrossRef
A rare association of paraneoplastic pemphigus with gastric signet cell ring carcinoma
Anfisa Lepekhova, Olga Olisova, Natalia Teplyuk, Dmitrii Zolotenkov, Anastasiia Allenova
Australasian Journal of Dermatology.2019;[Epub] CrossRef
Paraneoplastic autoimmune multiorgan syndrome (PAMS): Beyond the single phenotype of paraneoplastic pemphigus
Kyle T. Amber, Manuel Valdebran, Sergei A. Grando
Autoimmunity Reviews.2018; 17(10): 1002. CrossRef
Pemphigus
Patricia Chirinos-Saldaña, Alejandro Navas, Arturo Ramírez-Miranda, María Carmen Jiménez-Martínez, Enrique O. Graue-Hernández
Eye & Contact Lens: Science & Clinical Practice.2016; 42(2): 91. CrossRef

137,232 View
83 Download
10 Crossref

Implications of Bone-Only Metastases in Breast Cancer: Favorable Preference with Excellent Outcomes of Hormone Receptor Positive Breast Cancer: Su Jin Lee, Silvia Park, Hee Kyung Ahn, Jun Ho Yi, Eun Yoon Cho, Jong Mu Sun, Jeong Eon Lee, Seok Jin Nam, Jung-Hyun Yang, Yeon Hee Park, Jin Seok Ahn, Young-Hyuck Im; Cancer Res Treat. 2011;43(2):89-95. Published online June 30, 2011; DOI: https://doi.org/10.4143/crt.2011.43.2.89

Abstract PDF PubReader ePub

PURPOSE
The aim of the current study was to determine the incidence, clinical presentation, and treatment outcomes of "bone-only metastases" in patients with breast cancer and to analyze the impact of hormone receptor (HR) and human epidermal growth factor receptor 2 (HER2) status on prognosis.
MATERIALS AND METHODS
Between 1994 and 2007, of 968 patients with metastatic breast cancer who underwent palliative management at Samsung Medical Center, 565 (57%) relapsed with distant metastases. Of the 968, 146 (15%) had bone-only metastases during a median follow-up period of 75 months. Among the 146 patients with bone-only metastases, 122 (84%) were relapsed patients after curative surgery and 24 (26%) were initially metastatic cases.
RESULTS
The median time from primary surgery to bone-only metastases of the 122 patients was 37 months (95% confidence interval [CI], 27 to 46 months). Bone-only metastases were more common in the HR-positive group than in the other subtypes (85% for HR+; 8.2% for HER2+; 6.8% for triple negative. Among all 146 patients, 75 (51%) were treated with hormone therapy. The median post-relapse progression-free survival was 15 months (95%CI, 13 to 17 months). The median overall survival was much longer in the HR+ patients than the HER2+ and triple negative breast cancer patients with marginal statistical significance (65 vs. 40 vs. 40 months, p=0.077).
CONCLUSION
Breast cancer patients with "bone-only metastases" had excellent clinical outcomes. Further study is now warranted to reveal the underlying biology that regulates the behavior of this indolent tumor, as it should identify 'favorable tumor characteristics' in addition to 'favorable preferential metastatic site.'

Citations

Citations to this article as recorded by

Intersecting Paths: Unraveling the Complex Journey of Cancer to Bone Metastasis
Nour Arakil, Shahid Akhtar Akhund, Basant Elaasser, Khalid S. Mohammad
Biomedicines.2024; 12(5): 1075. CrossRef
Germacrone alleviates breast cancer‐associated osteolysis by inhibiting osteoclastogenesis via inhibition of MAPK/NF‐κB signaling pathways
Zhengjun Lin, Yaocheng Yang, Tang Liu, Ziyi Wu, Xianghong Zhang, Jing Yang
Phytotherapy Research.2024; 38(6): 2860. CrossRef
Acro metastasis: A rare presentation in a common cancer
Ali Ghanei-Shahmirzadi, Nasrin Namdari, Maral Mokhtari, Pooya Iranpour
Current Problems in Cancer: Case Reports.2024; 14: 100292. CrossRef
Concise review: breast cancer stems cells and their role in metastases
Mohammad Kamalabadi Farahani, Mohammad Farjadmehr, Amir Atashi, Alireza Momeni, Mahin Behzadifard
Annals of Medicine & Surgery.2024; 86(9): 5266. CrossRef
Breast cancers that disseminate to bone marrow acquire aggressive phenotypes through CX43-related tumor-stroma tunnels
Saptarshi Sinha, Brennan W. Callow, Alex P. Farfel, Suchismita Roy, Siyi Chen, Maria Masotti, Shrila Rajendran, Johanna M. Buschhaus, Celia R. Espinoza, Kathryn E. Luker, Pradipta Ghosh, Gary D. Luker
Journal of Clinical Investigation.2024;[Epub] CrossRef
Management of Oligometastatic Breast Cancer: An Expert Committee’s Opinion
Dominique Leblanc, Guy Cantin, Alexandra Desnoyers, Jean Dufresne, Giuseppina Laura Masucci, Valérie Panet-Raymond, Éric Poirier, Sara Soldera, Isabelle Gingras
Current Oncology.2023; 30(2): 1416. CrossRef
Surgery in the Setting of Metastatic Breast Cancer
Jennifer K. Plichta, Mahsa Taskindoust, Rachel A. Greenup
Current Breast Cancer Reports.2023; 15(1): 37. CrossRef
Team Approach: Management of Pathologic Fractures
Aws Hammad, Osman Ahmed, Philip P. Connell, Daniel Olson, Tessa Balach
JBJS Reviews.2023;[Epub] CrossRef
Diagnostic effectiveness of [18F]Fluoroestradiol PET/CT in oestrogen receptor-positive breast cancer: the key role of histopathology. Evidence from an international multicentre prospective study
Gianluca Bottoni, Francesco Fiz, Matteo Puntoni, Federica Matteucci, Manuela Monti, Andrea DeCensi, Oriana Nanni, Etienne Brain, Jean Louis Alberini, Bassam Dib, Gianmauro Sacchetti, Pierpaolo Trimboli, Giorgio Treglia, Nadia Harbeck, Simona Sola, Alessan
European Journal of Nuclear Medicine and Molecular Imaging.2023; 50(8): 2477. CrossRef
Plasma hPG80 (Circulating Progastrin) as a Novel Prognostic Biomarker for early-stage breast cancer in a breast cancer cohort
Alexandre Prieur, Andrew Harper, Momtafin Khan, Bérengère Vire, Dominique Joubert, Léa Payen, Karen Kopciuk
BMC Cancer.2023;[Epub] CrossRef
SCUBE2 mediates bone metastasis of luminal breast cancer by modulating immune-suppressive osteoblastic niches
Qiuyao Wu, Pu Tian, Dasa He, Zhenchang Jia, Yunfei He, Wenqian Luo, Xianzhe Lv, Yuan Wang, Peiyuan Zhang, Yajun Liang, Wenjin Zhao, Jun Qin, Peng Su, Yi-Zhou Jiang, Zhi-Ming Shao, Qifeng Yang, Guohong Hu
Cell Research.2023; 33(6): 464. CrossRef
Abemaciclib, Palbociclib, and Ribociclib in Real-World Data: A Direct Comparison of First-Line Treatment for Endocrine-Receptor-Positive Metastatic Breast Cancer
Mónica Cejuela, Ana Gil-Torralvo, M. Ángeles Castilla, M. Ángeles Domínguez-Cejudo, Alejandro Falcón, Marta Benavent, Sonia Molina-Pinelo, Manuel Ruiz-Borrego, Javier Salvador Bofill
International Journal of Molecular Sciences.2023; 24(10): 8488. CrossRef
Multidimensional analysis to elucidate the possible mechanism of bone metastasis in breast cancer
Kang Yao, Zhu Xiaojun, Zhao Tingxiao, Liao Shiyao, Ji Lichen, Zhang Wei, Li Yanlei, Tian Jinlong, Ding Xiaoyan, Zhang Jun, Bi Qing, Lv Jun
BMC Cancer.2023;[Epub] CrossRef
Diagnostic and Prognostic Role of 18F-Fluoroestradiol PET in Metastatic Breast Cancer: The Second Youth of an Older Theranostic Concept
Francesco Fiz, Gianluca Bottoni, Giorgio Treglia, Pierpaolo Trimboli, Arnoldo Piccardo
Journal of Clinical Medicine.2022; 11(13): 3589. CrossRef
Prominin 1 Significantly Correlated with Bone Metastasis of Breast Cancer and Influenced the Patient’s Prognosis
Cheng-cheng Yu, Yi-nan Wu, Kai-min Hu, Su-zhan Zhang, Ali Imran
BioMed Research International.2022;[Epub] CrossRef
Development of local injectable, bone-targeting nanocarriers of triptolide for treatment of bone-only metastasis
Wucheng Wen, Pengbo Guo, Hui Yi Xue, Ho Lun Wong
International Journal of Pharmaceutics.2022; 625: 122092. CrossRef
Clinical Characteristics, Prognostic Factors and Treatment Outcomes of Patients with Bone-Only Metastatic Breast Cancer
Lina Marie, Dina Braik, Nayef Abdel-Razeq, Hala Abu-Fares, Ahmad Al-Thunaibat, Hikmat Abdel-Razeq
Cancer Management and Research.2022; Volume 14: 2519. CrossRef
Bone Metastasis of Breast Cancer: Molecular Mechanisms and Therapeutic Strategies
Lulian Pang, Chen Gan, Jian Xu, Yingxue Jia, Jiaying Chai, Runze Huang, Anlong Li, Han Ge, Sheng Yu, Huaidong Cheng
Cancers.2022; 14(23): 5727. CrossRef
Is there a role for locoregional treatment of the primary tumor in de novo metastatic breast cancer in the era of tailored therapies?
E. Pons-Tostivint, E. Alouani, Y. Kirova, F. Dalenc, C. Vaysse
Critical Reviews in Oncology/Hematology.2021; 157: 103146. CrossRef
Leuprorelin combined with letrozole with/without everolimus in ovarian-suppressed premenopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer: The LEO study
Jae Ho Jeong, Jeong Eun Kim, Jin-Hee Ahn, Kyung Hae Jung, Su-Jin Koh, Jaekyung Cheon, Joohyuk Sohn, Gun Min Kim, Keun Seok Lee, Sung Hoon Sim, In Hae Park, Sung-Bae Kim
European Journal of Cancer.2021; 144: 341. CrossRef
Analysis of genomics and immune infiltration patterns of epithelial-mesenchymal transition related to metastatic breast cancer to bone
Shuzhong Liu, An Song, Yunxiao Wu, Siyuan Yao, Muchuan Wang, Tong Niu, Chengao Gao, Ziquan Li, Xi Zhou, Zhen Huo, Bo Yang, Yong Liu, Yipeng Wang
Translational Oncology.2021; 14(2): 100993. CrossRef
Trefoil factor-1 upregulation in estrogen-receptor positive breast cancer correlates with an increased risk of bone metastasis
Chiara Spadazzi, Laura Mercatali, Mark Esposito, Yong Wei, Chiara Liverani, Alessandro De Vita, Giacomo Miserocchi, Elisa Carretta, Michele Zanoni, Claudia Cocchi, Alberto Bongiovanni, Federica Recine, Yibin Kang, Toni Ibrahim
Bone.2021; 144: 115775. CrossRef
Diagnosis and referral of adults with suspected bony metastases
Samantha Downie, Elizabeth Bryden, Fergus Perks, A Hamish RW Simpson
BMJ.2021; : n98. CrossRef
Endocrine-Based Treatments in Clinically-Relevant Subgroups of Hormone Receptor-Positive/HER2-Negative Metastatic Breast Cancer: Systematic Review and Meta-Analysis
Francesco Schettini, Mario Giuliano, Fabiola Giudici, Benedetta Conte, Pietro De Placido, Sergio Venturini, Carla Rognoni, Angelo Di Leo, Mariavittoria Locci, Guy Jerusalem, Lucia Del Mastro, Fabio Puglisi, PierFranco Conte, Michelino De Laurentiis, Lajos
Cancers.2021; 13(6): 1458. CrossRef
Heterogeneity of bone metastases as an important prognostic factor in patients affected by oestrogen receptor-positive breast cancer. The role of combined [18F]Fluoroestradiol PET/CT and [18F]Fluorodeoxyglucose PET/CT
Gianluca Bottoni, Arnoldo Piccardo, Francesco Fiz, Giacomo Siri, Federica Matteucci, Andrea Rocca, Oriana Nanni, Manuela Monti, Etienne Brain, Jean Louis Alberini, Bassam Dib, Gian Mauro Sacchetti, Chiara Saggia, Valentina Rossi, Nadia Harbeck, Rachel Wue
European Journal of Radiology.2021; 141: 109821. CrossRef
Locoregional therapy in de novo metastatic breast cancer: Systemic review and meta-analysis
Daniel Reinhorn, Raz Mutai, Rinat Yerushalmi, Assaf Moore, Eitan Amir, Hadar Goldvaser
The Breast.2021; 58: 173. CrossRef
Exosomal miR-19a and IBSP cooperate to induce osteolytic bone metastasis of estrogen receptor-positive breast cancer
Kerui Wu, Jiamei Feng, Feng Lyu, Fei Xing, Sambad Sharma, Yin Liu, Shih-Ying Wu, Dan Zhao, Abhishek Tyagi, Ravindra Pramod Deshpande, Xinhong Pei, Marco Gabril Ruiz, Hiroyuki Takahashi, Shunsuke Tsuzuki, Takahiro Kimura, Yin-yuan Mo, Yusuke Shiozawa, Ravi
Nature Communications.2021;[Epub] CrossRef
Incidence of Brain Metastases in Nonmetastatic and Metastatic Breast Cancer: Is There a Role for Screening?
Adam S. Komorowski, Ellen Warner, Helen J. MacKay, Arjun Sahgal, Kathleen I. Pritchard, Katarzyna J. Jerzak
Clinical Breast Cancer.2020; 20(1): e54. CrossRef
Radiation therapy for bone-only metastases in breast cancer patients: A GOCO survey of current clinical practice
Marta Bonet, Virginia García, Núria Farré, Manel Algara, Blanca Farrús, Jaume Fernandez, Victoria Reyes, Arancha Eraso, Ana Álvarez, Maria José Cambra, Agustí Pedro, Jordi Vayreda, Claire Lemansky, Françoise Izar, Meritxell Arenas
Reports of Practical Oncology & Radiotherapy.2020; 25(1): 113. CrossRef
MicroRNA-429 inhibits bone metastasis in breast cancer by regulating CrkL and MMP-9
Xinxin Zhang, Xiying Yu, Zhenguo Zhao, Zhennan Yuan, Peiqing Ma, Zhibin Ye, Liping Guo, Songfeng Xu, Libin Xu, Ting Liu, Huanmei Liu, Shengji Yu
Bone.2020; 130: 115139. CrossRef
Metastatic Presentations of Previously Treated Early-Stage Breast Cancer Patients and Association With Survival
Najla Itani, Nicole Grogan, Sarah Mott, Sneha Phadke
Clinical Breast Cancer.2020; 20(3): 209. CrossRef
Concordance of real-world versus conventional progression-free survival from a phase 3 trial of endocrine therapy as first-line treatment for metastatic breast cancer
Cynthia Huang Bartlett, Jack Mardekian, Matthew James Cotter, Xin Huang, Zhe Zhang, Christina M. Parrinello, Ariel Bulua Bourla, Apar Kishor Ganti
PLOS ONE.2020; 15(4): e0227256. CrossRef
International Framework for Red Flags for Potential Serious Spinal Pathologies
Laura M. Finucane, Aron Downie, Christopher Mercer, Susan M. Greenhalgh, William G. Boissonnault, Annelies L. Pool-Goudzwaard, Jason M. Beneciuk, Rachel L. Leech, James Selfe
Journal of Orthopaedic & Sports Physical Therapy.2020; 50(7): 350. CrossRef
Prognostic Value of Modified IHC4 Score in Patients with Estrogen Receptor-Positive Metastatic Breast Cancer
Liang Jin, Kai Chen, Cui Tan, Jianbin Li, Jiayue Luo, Yaping Yang, Yudong Li, Shunying Li, Liling Zhu, Yue Hu, Fengtao Liu, Qiuting You, Min Peng, Zefei Jiang, Qiang Liu
The Oncologist.2020; 25(8): e1170. CrossRef
Imaging diagnosis of metastatic breast cancer
Filippo Pesapane, Kate Downey, Anna Rotili, Enrico Cassano, Dow-Mu Koh
Insights into Imaging.2020;[Epub] CrossRef
Tamoxifen Rechallenge Decreases Metastatic Potential but Increases Cell Viability and Clonogenicity in a Tamoxifen-Mediated Cytotoxicity-Resistant Subline of Human Breast MCF7 Cancer Cells
Yung-Chieh Chang, Chun Hei Antonio Cheung, Yao-Lung Kuo
Frontiers in Cell and Developmental Biology.2020;[Epub] CrossRef
Treatment effect of palbociclib plus endocrine therapy by prognostic and intrinsic subtype and biomarker analysis in patients with bone-only disease: a joint analysis of PALOMA-2 and PALOMA-3 clinical trials
Richard S. Finn, Massimo Cristofanilli, Johannes Ettl, Karen A. Gelmon, Marco Colleoni, Carla Giorgetti, Eric Gauthier, Yuan Liu, Dongrui R. Lu, Zhe Zhang, Cynthia Huang Bartlett, Dennis J. Slamon, Nicholas C. Turner, Hope S. Rugo
Breast Cancer Research and Treatment.2020; 184(1): 23. CrossRef
Innovative Options for Bone Metastasis Treatment: An Extensive Analysis on Biomaterials-Based Strategies for Orthopedic Surgeons
Ania Naila Guerrieri, Monica Montesi, Simone Sprio, Roberta Laranga, Laura Mercatali, Anna Tampieri, Davide Maria Donati, Enrico Lucarelli
Frontiers in Bioengineering and Biotechnology.2020;[Epub] CrossRef
The influence of breast cancer subtype on survival after palliative radiation for osseous metastases
Mohamed K. Abdelhakiem, Candice Johnstone, Carmen Bergom, Adam Currey, Jared R. Robbins
Cancer Medicine.2020; 9(23): 8979. CrossRef
Racial/ethnic differences in the outcomes of patients with metastatic breast cancer: contributions of demographic, socioeconomic, tumor and metastatic characteristics
Jin-Xiao Ren, Yue Gong, Hong Ling, Xin Hu, Zhi-Ming Shao
Breast Cancer Research and Treatment.2019; 173(1): 225. CrossRef
Metastatic pattern discriminates survival benefit of primary surgery for de novo stage IV breast cancer: A real-world observational study
Kang Wang, Yang Shi, Zhu-Yue Li, Ye-Lei Xiao, Jie Li, Xiang Zhang, Hong-Yuan Li
European Journal of Surgical Oncology.2019; 45(8): 1364. CrossRef
The CXCL5/CXCR2 axis is sufficient to promote breast cancer colonization during bone metastasis
Ricardo Romero-Moreno, Kimberly J. Curtis, Thomas R. Coughlin, Maria Cristina Miranda-Vergara, Shourik Dutta, Aishwarya Natarajan, Beth A. Facchine, Kristen M. Jackson, Lukas Nystrom, Jun Li, William Kaliney, Glen L. Niebur, Laurie E. Littlepage
Nature Communications.2019;[Epub] CrossRef
Single-Agent Oral Vinorelbine as First-Line Chemotherapy for Endocrine-Pretreated Breast Cancer With Bone Metastases and No Visceral Involvement: NORBREAST-228 Phase II Study
Guenther G. Steger, Adriana Dominguez, Natalia Dobrovolskaya, Francesco Giotta, Nicole Tubiana-Mathieu, Martin Pecherstorfer, Antonio Ardizzoia, Maria Blasinska-Morawiec, Enrique Espinosa, Gustavo Villanova
Clinical Breast Cancer.2018; 18(1): e41. CrossRef
Differential presentation and survival of de novo and recurrent metastatic breast cancer over time: 1990–2010
Judith A. Malmgren, Musa Mayer, Mary K. Atwood, Henry G. Kaplan
Breast Cancer Research and Treatment.2018; 167(2): 579. CrossRef
Breast cancer bone metastases: pathogenesis and therapeutic targets
Naomi Brook, Emily Brook, Arun Dharmarajan, Crispin R. Dass, Arlene Chan
The International Journal of Biochemistry & Cell Biology.2018; 96: 63. CrossRef
Incidence, risk factors and prognostic characteristics of bone metastases and skeletal-related events (SREs) in breast cancer patients: A systematic review of the real world data
Hongwei Zhang, Wei Zhu, Ewelina Biskup, Weige Yang, Ziang Yang, Hong Wang, Xiaochun Qiu, Chengjiao Zhang, Guangxia Hu, Guangfu Hu
Journal of Bone Oncology.2018; 11: 38. CrossRef
Breast osteoblast-like cells: a new biomarker for the management of breast cancer
Manuel Scimeca, Nicoletta Urbano, Rita Bonfiglio, Orazio Schillaci, Elena Bonanno
British Journal of Cancer.2018; 119(9): 1129. CrossRef
Post-relapse survival in patients with the early and late distant recurrence in estrogen receptor-positive HER2-negative breast cancer
Akiko Ogiya, Kieko Yamazaki, Rie Horii, Tadahiko Shien, Yoshiya Horimoto, Norikazu Masuda, Touko Inao, Mitsuchika Hosoda, Naoko Ishida, Tomofumi Osako, Masato Takahashi, Yumi Endo, Yuichiro Miyoshi, Hiroyuki Yasojima, Nobumoto Tomioka, Hiroko Yamashita
Breast Cancer.2017; 24(3): 473. CrossRef
Pattern of metastatic spread and subcategories of breast cancer
Catharina Bartmann, Manfred Wischnewsky, Tanja Stüber, Roland Stein, Mathias Krockenberger, Sebastian Häusler, Wolfgang Janni, Rolf Kreienberg, Maria Blettner, Lukas Schwentner, Achim Wöckel, Joachim Diessner
Archives of Gynecology and Obstetrics.2017; 295(1): 211. CrossRef
Osteonecrosis of the Jaw in a Breast Cancer Patient Treated with Everolimus and a Single Dose of Zoledronic Acid
Claudia Omarini, Maria E. Filieri, Roberta Depenni, Giulia Grizzi, Stefano Cascinu, Federico Piacentini
The Breast Journal.2017; 23(5): 610. CrossRef
The critical role of the ZNF217 oncogene in promoting breast cancer metastasis to the bone
Aurélie Bellanger, Caterina F Donini, Julie A Vendrell, Jonathan Lavaud, Irma Machuca‐Gayet, Maëva Ruel, Julien Vollaire, Evelyne Grisard, Balázs Győrffy, Ivan Bièche, Olivier Peyruchaud, Jean‐Luc Coll, Isabelle Treilleux, Véronique Maguer‐Satta, Véroniqu
The Journal of Pathology.2017; 242(1): 73. CrossRef
Estrogen receptors in breast and bone: from virtue of remodeling to vileness of metastasis
I Bado, Z Gugala, S A W Fuqua, X H-F Zhang
Oncogene.2017; 36(32): 4527. CrossRef
Which red flags aid the early detection of metastatic bone disease in back pain?
Laura Finucane, Susan Greenhalgh, James Selfe
Physiotherapy Practice and Research.2017; 38(2): 73. CrossRef
Prognostic utility of FDG PET/CT and bone scintigraphy in breast cancer patients with bone-only metastasis
Soyeon Park, Joon-Kee Yoon, Su Jin Lee, Seok Yun Kang, Hyunee Yim, Young-Sil An
Medicine.2017; 96(50): e8985. CrossRef
Tolerability of Therapies Recommended for the Treatment of Hormone Receptor-Positive Locally Advanced or Metastatic Breast Cancer
Shinji Ohno
Clinical Breast Cancer.2016; 16(4): 238. CrossRef
Quality of life and symptom burden in patients with metastatic breast cancer
Christine Ecclestone, Ronald Chow, Natalie Pulenzas, Liying Zhang, Angela Leahey, Julia Hamer, Carlo DeAngelis, Gillian Bedard, Rachel McDonald, Anchal Bhatia, Janet Ellis, Eileen Rakovitch, Sherlyn Vuong, Edward Chow, Sunil Verma
Supportive Care in Cancer.2016; 24(9): 4035. CrossRef
Evaluation of clinical parameters influencing the development of bone metastasis in breast cancer
Joachim Diessner, Manfred Wischnewsky, Tanja Stüber, Roland Stein, Mathias Krockenberger, Sebastian Häusler, Wolfgang Janni, Rolf Kreienberg, Maria Blettner, Lukas Schwentner, Achim Wöckel, Catharina Bartmann
BMC Cancer.2016;[Epub] CrossRef
Prolactin receptor in breast cancer: marker for metastatic risk
Carrie S Shemanko
Journal of Molecular Endocrinology.2016; 57(4): R153. CrossRef
Clinical Characteristics and Outcome of Bone-Only Metastasis in Inflammatory and Noninflammatory Breast Cancers
Megumi Kai, Takahiro Kogawa, Diane D. Liu, Tamer M. Fouad, Kazuharu Kai, Naoki Niikura, Limin Hsu, Jie S. Willey, Richard L. Theriault, Vicente Valero, Naoto T. Ueno
Clinical Breast Cancer.2015; 15(1): 37. CrossRef
Loading Dose Ibandronate Versus Standard Oral Ibandronate in Patients With Bone Metastases From Breast Cancer
Iain R. Macpherson, Caroline Bray, Carol Hopkins, Rosemary A. Hannon, Liz-Anne Lewsley, Diana M. Ritchie, Peter Canney
Clinical Breast Cancer.2015; 15(2): 117. CrossRef
Assessing response to treatment of bone metastases from breast cancer: what should be the standard of care?
D.K. Woolf, A.R. Padhani, A. Makris
Annals of Oncology.2015; 26(6): 1048. CrossRef
Survival time according to the year of recurrence and subtype in recurrent breast cancer
Masahiro Nakano, Mamiko Fujisue, Rumiko Tashima, Yasuhiro Okumura, Yasuyuki Nishiyama, Tomofumi Ohsako, Yasuo Toyozumi, Nobuyuki Arima, Reiki Nishimura
The Breast.2015; 24(5): 588. CrossRef
Cases of Bone-only Metastasis in Recurrent Breast Cancer
Yoko MAEKAWA, Shintaro TAKAO, Koichi HIROKAGA, Mayuko MIKI, Sachiko YOSHIDA
Nihon Rinsho Geka Gakkai Zasshi (Journal of Japan Surgical Association).2014; 75(6): 1484. CrossRef
Efficacy of Exemestane in Korean Patients with Metastatic Breast Cancer after Failure of Nonsteroidal Aromatase Inhibitors
June Koo Lee, Seock-Ah Im, Daewon Lee, Ji-Yeon Kim, Yoojoo Lim, Eunyoung Lee, Hyeong-Gon Moon, Tae-Yong Kim, Sae-Won Han, Do-Youn Oh, Se-Hoon Lee, Wonshik Han, Dong-Wan Kim, Tae-You Kim, Dong-Young Noh
Journal of Breast Cancer.2013; 16(1): 66. CrossRef
Incidence, consequences and treatment of bone metastases in breast cancer patients—Experience from a single cancer centre
I. Kuchuk, B. Hutton, P. Moretto, T. Ng, C.L. Addison, M. Clemons
Journal of Bone Oncology.2013; 2(4): 137. CrossRef
Zooming in on the schedule of bone-modifying drugs
Miguel Martin, Sara López-Tarruella
The Lancet Oncology.2013; 14(7): 575. CrossRef
Bone metastases: assessment, management and treatment options
Carole Farrell
British Journal of Nursing.2013; 22(Sup7): S4. CrossRef
Limites de la scintigraphie osseuse dans le suivi des métastases osseuses du carcinome mammaire : étude du centre tunisien
K. Chatti, A. Harrabi, I. Chabchoub, T. Kamoun, R. Sfar, M. Nouira, M.B. Fredj, N. Ayachi, S.B. Ahmed, H. Essabbah
Médecine Nucléaire.2012; 36(10): 574. CrossRef

16,117 View
148 Download
68 Crossref

Significant Dissatisfaction with the Anachronistic System: A Survey on The Experience of Application for Off-Label Use of Anti-Cancer Drugs by Korean Society of Medical Oncology: Jae Lyun Lee, Dong-Hoe Koo, Young-Woong Won, Young Saing Kim, Hee Kyung Ahn, Seungtaek Lim; Received August 7, 2024 Accepted February 10, 2025 Published online February 11, 2025; DOI: https://doi.org/10.4143/crt.2024.749 [Accepted]

Abstract PDF: Purpose
This study evaluates the experiences and satisfaction levels of Korean medical oncologists with the prior authorization system for the off-label use of anti-cancer drugs. Conducted by the Korean Society of Medical Oncology (KSMO), the survey aimed to identify challenges and areas for improvement in the current regulatory framework.
Materials and Methods
A cross-sectional web-based survey was carried out between May 4 and May 14, 2023, targeting 261 active KSMO medical oncologists. Invitations were sent via email, and the survey, comprising 19 questions, was hosted on Microsoft Forms. The questions covered personal characteristics, work environment, experiences with the pre-application process, and post-approval experiences.
Results
For the 261 invitations sent, 110 responses (42.1%) were received. Most respondents had over 10 years of experience and worked in tertiary hospitals. Although 93.6% were familiar with the pre-application system, 67.3% expressed moderate to high dissatisfaction. The key issues included complex applications, long approval period, stringent criteria, and inconsistent reviews. Additionally, 74.4% respondents spent over 3 hours on first-time applications, with 68.3% experiencing rejections. Emotional responses to rejections were largely negative, with many feeling disregarded. Post-approval, patients of 96.8% respondents faced financial burdens leading to treatment discontinuation. Most oncologists (86.0%) supported selective reimbursement if the disease was controlled for a certain period.
Conclusion
The survey highlights significant dissatisfaction with the current system, suggesting the need for streamlining the application process, easing approval criteria, and reconsidering the financial aspects of post-approval treatments to support patient care and oncologists’ decision-making autonomy.

260 View
20 Download

The Impact of Obesity on Treatment Outcomes in Patients with Hormone Receptor-Positive HER2-Negative Metastatic Breast Cancer Receiving CDK 4/6 Inhibitors: Yoo Bin Jung, Hee Kyung Ahn, Hyun-Young Shin, Ji Hyung Hong, Chai Hong Rim; Received January 25, 2025 Accepted April 13, 2025 Published online April 15, 2025; DOI: https://doi.org/10.4143/crt.2025.110 [Accepted]

Abstract PDF: Purpose
Guidelines from the aromatase inhibitor era for early breast cancer (EBC) treatment recommend maintaining a body mass index (BMI) below 25. In the current era of CDK 4/6 inhibitors, now standard in metastatic breast cancer (MBC), limited data exist on treatment outcomes in obese patients. This study investigates how adiposity affects the treatment outcome of CDK 4/6 inhibitors in patients with hormone receptor (HR)-positive, HER2-negative MBC.
Materials and Methods
We searched PubMed, MEDLINE, and Embase databases, assessing efficacy outcomes such as progression-free survival (PFS) based on obesity markers, including BMI and visceral adipose tissue (VAT) index.
Results
Twelve studies were reviewed, with seven studies and 1,812 patients included in a pooled meta-analysis. Among patients with BMI ≥25, modest improvement in PFS was observed, with a pooled hazard ratio (HR) of 0.944 (95% CI, 0.909-0.980; p = 0.003). Besides, add-on analysis using VAT to define obesity revealed a notable PFS improvement, with a pooled HR of 0.452 (95% CI, 0.256-0.798; p = 0.006).
Conclusion
While BMI-defined obesity showed slight PFS improvement with CDK 4/6 inhibitors and endocrine therapy, using VAT to define obesity revealed significant PFS gains. This highlights the need for further research on biomarker to clarify the role of adiposity in MBC, which may differ from its impact in EBC.

303 View
29 Download

Author index